CN101291668A - Atr抑制剂 - Google Patents
Atr抑制剂 Download PDFInfo
- Publication number
- CN101291668A CN101291668A CNA2006800391066A CN200680039106A CN101291668A CN 101291668 A CN101291668 A CN 101291668A CN A2006800391066 A CNA2006800391066 A CN A2006800391066A CN 200680039106 A CN200680039106 A CN 200680039106A CN 101291668 A CN101291668 A CN 101291668A
- Authority
- CN
- China
- Prior art keywords
- leu
- ser
- glu
- lys
- val
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/70—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with ring systems containing two or more relevant rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明的目的在于提供一种ATR抑制剂,其含有作为ATR蛋白质激酶抑制剂有用的各种五味子素类和戈米辛类等的三环性化合物作为有效成分。
Description
技术领域
本发明涉及一种抑制ATR(毛细血管扩张性共济失调突变和rad3相关的;ataxia-telangiectasia mutated and rad3-related)活性的ATR抑制剂,具体涉及一种含有三环性化合物作为有效成分的ATR抑制剂。
背景技术
已知ATM(毛细血管扩张性共济失调突变;ataxia-telangiectasia mutated)和ATR(毛细血管扩张性共济失调突变和rad3相关的;ataxia-telangiectasia mutated and rad3-related)蛋白质激酶(以下只称为ATM和ATR),在细胞的DNA损伤相关的修复中扮演着重要的角色(非专利文献1)。通过紫外线(UV)和电离放射(IR)照射,细胞受到DNA损伤,引起关卡信号级联(cascade),为了修复DNA损伤引起细胞凋亡,细胞周期停止于G1/S、中间S期及G2/M期。缺失ATM的AT(毛细血管扩张性共济失调症)患者来源的细胞由于呈现缺少G1/S和G2/M期关卡(checkpoint)的表现型,因此对IR具有感受性,因此,ATM及其下游的途径对维持染色体很重要。而且,由于一度或稳定的ATR的缺失,染色体的稳定性显著受损,或者在初期胚阶段达到致死(非专利文献2)。令人感兴趣的是,现在已知ATR产生的p53蛋白质(以下只称为p53)或NBS1的磷酸化由于ATM的存在而延迟。这提示,ATR在DNA损伤反应这一点上,是一种ATM的协调分子种类。事实上,ATR在防御DNA损伤中起着核心的作用。这些事项表明,ATM或ATR活性的控制不但是维持染色体的稳定性所必需的,而且也可以应用于化学疗法和放射线治疗等抗癌治疗中。
非专利文献3公开了由咖啡因(3,7-二氢-1,3,7-三甲基-1H-嘌呤-2,6二酮)辅助的化学疗法,以最小限度解决与非增殖性的骨肉瘤相关的肿瘤的切除。人们认为咖啡因与由化学疗法中引起的DNA损伤相反应,抑制ATM和ATR的蛋白质激酶活性,但已知咖啡因相对于ATR而言,更能抑制ATM。
近年来,通过siRNA转染细胞,重组体的激酶使激酶活性部位缺失的蛋白质过度表达等,从而清楚了ATR和ATM的主要功能(非专利文献4-6)。但是,由于稳定的敲除了ATR的小鼠是致死的,因此与ATM相比,很少有报道ATR的功能的例子。而且,在不知道ATR的特异性抑制剂的现状中,使用咖啡因和PI3激酶的抑制剂-Wortmannin,广泛进行了化学抑制ATM和ATR的蛋白质激酶活性的研究。因此,通过研究出ATR的特异性抑制剂,对于DNA损伤应答反应中生物化学的信息,进而在抗癌治疗的研究有许多优点,因此期盼抑制ATR活性的药物。
这其中,ATM和ATR在细胞中对应于DNA损伤的反应期间,对p53的第15位的丝氨酸残基进行磷酸化。p53在由DNA损伤诱导的G1/S关卡中,起着核心的作用。根据近年来的认识表明:暴露于UV光时,p53的第15位的丝氨酸残基直接被ATM或ATR磷酸化,发生G1期的细胞周期停止。因此,p53的第15位的丝氨酸残基的磷酸化是评价在由UV诱导的DNA损伤后以ATM或ATR作为起点的G1/S关卡是否起作用的合适指标。而且,这种磷酸化在对应于UV的损伤反应中反映ATR的活性。G2/M关卡与G1/S同样,在DNA损伤细胞中受到ATM和ATR的调控。G2/M关卡十分重要,在p53缺失或突变肿瘤等许多癌细胞中很好地保存。尤其是,缺失p53功能的细胞和G2/M关卡的废止对DNA损伤具有感受性。事实上,与G2/M关卡相关时,ATR对于分裂细胞的染色体维持十分重要。这些结果提示:包括ATR蛋白激酶活性的抑制在内的与G2/M关卡相关的一组的抑制成为抗癌治疗的候补方法。
另一方面,来源于五味子(Schisandrae Fructus)的各种五味子素类和戈米辛(gomisin)类是二苄基环辛烷基因衍生物,是作为生物药剂最常使用的化合物类群。作为该化合物类群中一种的有用性,非专利文献8公开了在SMMC-7721肝癌细胞中,五味子素B诱导Caspase-3依赖性细胞凋亡。人们希望对这种化合物在包括肿瘤在内的多种细胞中产生的其它信号调节物质或其它效果展开进一步的研究。一直以来人们所相信的是,根据中国数千年的经验,在含有各种五味子素类和戈米辛类的传统生药、五味子中残留了许多可能性。抗癌剂的70%以上来源于天然物质,或希望副作用更少的类似物。本申请申请人,在抗癌治疗增感剂的观点来看,想到将各种五味子素类和戈米辛类应用于与DNA损伤相关的反应中的信号传递途径中。
专利文献1:特开平7-206751号公报
专利文献2:特开平6-192133号公报
专利文献3:特开平2-48592号公报
专利文献4:特开平5-123184号公报
专利文献5:美国专利申请公开号第2005/0282910号说明书
非专利文献1:Shiloh Y箸,“ATM and ATR:networking cellularresponses to DNA damage”,Curr Opin.Genet.Dev.,2001年,11卷,71-7页
非专利文献2:Cortez D等箸,“ATR and ATRIP:partners incheckpoint signaling”,Science,2001年,294卷,1713-6页
非专利文献3:Tsuchiya H等箸,“Caffeine-assistedchemotherapy and min imized tumor excision for nonmetastaticosteosarcoma.”,Anticancer Res.,1998年,18卷,657-66页
非专利文献4:Shackelford RE等著,“The Ataxiatelangiectasia gene product is required for oxidativestress-induced G1 and G2 checkpoint function in humanfibroblasts.”,J.Biol.Chem.,2001年,276卷,21951-9页
非专利文献5:Wright JA等箸,“Protein kinase mutants ofhuman ATR increase sensitivity to UV and ionizing radiation andabrogate cell cycle checkpoint control.”,Proc.Natl.Acad.Sci.USA.,1998年,95卷,7445-50页
非专利文献6:Shigeta T等箸,“Defective control of apoptosisand mitotic spindle checkpoint in heterozygous carriers of ATMmutations.”,Cancer Res.,1999年,59卷,2602-7页
非专利文献7:Sarkaria JN等著,“Inhibition of ATM and ATRkinase activities by the radiosensitizing agent,caffeine.”,Cancer Res.,1999年,59卷,4375-82页
非专利文献8:Wu YF等箸,“Down-modulation of heat shockprotein 70 and up-modulation of Caspase-3 during schisandrinB-induced apoptosis in human hepatoma SMMC-7221 cells”,WorldJ.Gastroenterol,2004年,10卷,2944-48页
非专利文献9:Tibbetts等箸,Gene & Development,2000年,14卷,2989-3002页
非专利文献10:Canman等著,Science,1998等281卷,1677-9页
非专利文献11:Rouet等著,Proc.Natl.Acad.Scie.USA,1994年,91卷,6064-8页
非专利文献12:Chem.Pharm.Bull.,2003年,51卷,11号,1233-1236页
非专利文献13:Acta Pharmacologica Sinica,1998年,19卷,4号,313-316页
发明内容
发明要解决的问题
因此,本发明目的在于提供一种ATR抑制剂,其含有作为ATR蛋白质激酶抑制剂有用的各种五味子素类和戈米辛等三环性化合物作为有效成分。
用于解决问题的手段
本发明的ATR抑制剂的特征在于含有下式(1)所示的化合物作为有效成分:
而且,本发明的ATR抑制剂的特征在于含有下式(2)所示的化合物作为有效成分:
而且,本发明的ATR抑制剂的特征在于含有下式(3)所示的化合物作为有效成分:
而且,本发明的ATR抑制剂的特征在于含有下式(4)所示的化合物作为有效成分:
而且,本发明的ATR抑制剂的特征在于含有下式(5)所示的化合物作为有效成分:
而且,本发明的ATR抑制剂的特征在于含有下式(6)所示的化合物作为有效成分:
而且,本发明的ATR抑制剂的特征在于含有下式(7)所示的化合物作为有效成分:
而且,本发明的ATR抑制剂的特征在于含有下式(8)所示的化合物作为有效成分:
而且,本发明的ATR抑制剂的特征在于含有下式(9)所示的化合物作为有效成分:
而且,本发明的ATR抑制剂的特征在于含有下式(10)所示的化合物作为有效成分:
其中,作为本发明的ATR抑制剂,优选含有上式(1)-(5)所示的化合物作为有效成分。
本发明的ATR抑制剂中,前述ATR活性优选为蛋白质磷酸化活性。
本发明的ATR抑制剂中,前述蛋白质磷酸化活性优选为对细胞周期关联蛋白质进行磷酸化的活性。
本发明的ATR抑制剂中,前述细胞周期关联蛋白质优选为p53。
本发明的ATR抑制剂中,前述细胞周期关联蛋白质优选为选自于Brca1和Chk1构成的组中。
发明的效果
如果按照本发明,可以在体内和体外特异性抑制ATR活性。
附图说明
图1:是表示经UV照射的A549细胞中五味子素B对生存率的影响的图。
图2:是表示经UV照射的A549细胞中五味子素B对细胞周期的影响的图,(A)是表示对总细胞数的磷酸化组蛋白H3量的图,(B)是表示以磷酸化组蛋白H3量作为指标,将分裂细胞数在所有细胞中所占比率图像化的图。
图3:是表示经电离放射线照射的A549细胞中五味子素B对分裂细胞数的影响的图。
图4:是表示经UV照射或电离放射线照射的A549细胞中五味子素B对p53磷酸化的影响的图。
图5-1:是表示经UV照射的A549细胞中五味子素B对p53磷酸化的浓度依赖性影响的图。
图5-2:是表示经UV照射的A549细胞中ATR抑制剂对p 53磷酸化的影响的图。
图6:是表示A549细胞中五味子素B对细胞周期的影响的图。
图7:是表示五味子素B对ATR和ATM所具有的磷酸化活性的影响的图,(A)为对应于ATR的图,(B)是对应于ATM的图。
图8:是表示经UV照射的AT2KY细胞中,五味子素B对各种蛋白的磷酸化的影响的图。
图9:是表示经抑制ATR或ATM表达的UV照射的A549细胞中,五味子素B对各种蛋白的磷酸化的影响的图。
图10:是表示A549细胞中,五味子素B对MAPK的磷酸化的影响的图。
具体实施方式
本发明的ATR抑制剂可以利用合成产品、天然产品等各种市售的可以利用的化合物,也可以按照专利文献1等中记载的公知的合成方法制备,而且,也可以是按照专利文献2等公知的方法从五味子(Schisandra Chinensis)来源的Fructus Schisandrae等天然生药中提取/纯化出的物质。
具体是,作为上式(1)所示的五味子素B(Schizandrin B;SchB),可以是通过以下方式获得:如专利文献2中的记载,用n-已烷等烃类溶剂或甲醇等醇类溶剂加热一定时间提取五味子(FructusSchisandrae)后,置于柱层析,对含有所获得的非水溶性物质和水溶性物质的混合物的溶液浓缩干燥,在其中添加氢氧化钾和甲醇的混合液进行皂化,在这样获得的原料中加入甲醇搅拌溶解后,用氢氧化钾水溶液溶解,然后除去上述甲醇,析出目的物质的非水溶性物质。
而且,作为上式(2)所示的戈米辛C(Gomisin C;GC),可以通过以下方式获得:如上述专利文献3所示的方法,用石油醚等弱极性溶剂提取后,再使用石油醚,n-庚烷等弱极性水不溶性溶剂和甲醇等高极性水溶性溶剂进行分配提取后,根据需要用柱层析、通过高效液相层析等分离目的物质。
而且,作为上式(3)所示的戈米辛G(Gomisin G;GG),可以是如上述非专利文献12中所示,从阿里山五味子(Schizandra arisanensis)的干燥干中用乙酸乙酯提取,根据需要用柱层析进行纯化的制品。
而且,作为上式(4)所示的戈米辛H(Gomisin H;HG),可以如上述专利文献5中记载,从北五味子(Schizandra chinensis)中获得。
而且,作为上式(5)所示的戈米辛J(Gomisin J;GJ),可以通过专利文献1中所示的内容,在获得通过将从五味子中提取的脱氧五味子素酰基化合成的下式(B)所示的化合物后,脱烷基(式中的R1基),脱酰基化(式中,COR基)获得。
(式中,R1表示低级烷基,R表示氢原子或低级烷基)。
而且,上式(6)所示的五味子素(Schizandrin;Sch),可以如专利文献3所示,用石油醚等低极性溶剂和甲醇等高极性水溶性溶剂进行分配提取后,根据需要,通过柱层析、高效液相色谱等分离目的物质。
而且,作为上式(7)所示的戈米辛A(Gomisin A;GA),可以通过以下方式获得:除按照上述专利文献3的方法之外,如专利文献4中的记载,还原下式(A)所示化合物的5元环二羟基化后,再进行氧化反应、甲磺酰化反应,从获得的d1-五味子素(III)中分离旋光异构体。
而且,作为上式(8)所示的戈米辛B(Gomisin B;GB),可以通过以下方式获得:通过按照上述非专利文献12中记载的内容,用乙酸乙酯从阿里山五味子(Schizandra arisanensis)的干燥干中进行提取,根据需要使用柱层析进行纯化。
而且,上式(9)所示的戈米辛N(Gomisin N;GN),可以通过专利文献5中记载的内容,来源于北五味子(Schizandra chinensis)。
而且,上式(10)所示的五味子素C(Schizandrin c;SC),可以通过非专利文献13所示内容,使用五味子的石油醚提取物通过柱层析纯化获得。
实施例
(实施例1)经UV照射的A549细胞中五味子素B对生存率的影响
将A549细胞(American Tissue Type Collection公司制)以500个/60mm皿接种于含有10%胎儿牛血清(FBS)、100μg/mL链霉素和100个单位/mL青霉素的DMEM培养基(以下称为增殖培养基)中培养一昼夜后,在培养基中以1μM和10μM的终浓度添加五味子素B(制备含有终浓度为10g/L的五味子素B的DMSO溶液,再在培养基中稀释成培养基中不到5g/L的DMSO浓度,再使用。以下相同)。
添加1小时后,用Stratalinker(Stratagene公司制)照射20和50J/cm2的UV(波长采用254nm。以下相同),再次更换成具有与上述同浓度的五味子素B的培养基(以下,称为含有五味子素B的培养基),再连续培养14天后,用磷酸缓冲生理盐水(PBS)清洗细胞,用2%亚甲蓝,按照克隆法,计算存活的细胞数。结果示于图1。图1,横轴表示照射的UV的剂量,纵轴以百分比表示相对于未处理组,处理组中存活细胞的比率。图中,○表示没有用五味子素B处理的组,▲表示经1μM的五味子素B处理的组,■表示经10μM的五味子素B处理的组。而且,用平均±标准误差(n=3)表示各组。
(实施例2-1)经UV照射的A549细胞中五味子素B产生的对细胞周期的影响
在增殖培养基中以3×104个/cm2的终浓度在10mm皿中接种A549细胞,培养一昼夜后,以30μM的终浓度在培养基中添加五味子素B。1小时后,除去培养基,照射20和50J/m2的UV,在含有与上述浓度相同的五味子素B的培养基中培养细胞1小时。然后,按照下述的组蛋白H3磷酸化量的测定,测定细胞中的组蛋白H3磷酸化量。结果示于图2。图2(A)为经五味子素B处理时获得的流式细胞仪测试的结果,图2(A)中,圆圈中的部分表示G2/M期的细胞群,其上方记载的数据表示G2/M期的细胞群数相对于总细胞数的比率。而且,图2(B)为以图形表示该比率的图。
(实施例2-2)
在实施例2-1中,除了照射20J/m2的UV代替20和50J/m2的UV,使用上式(1)-(10)中所示的化合物和下式(C)所示的当归酰戈米辛A(Angeloygomisin A;AGA)(终浓度30μM)代替终浓度为30μM的五味子素B之外,进行与实施例2-1相同的步骤,获得了G2/M期的细胞群数相对于总细胞数的比率。结果示于表1。
[表1]
(实施例3)经电离放射线照射的A549细胞中五味子素B对分裂细胞数的影响
在增殖培养基中以3×104个/cm2的终浓度在10mm皿中接种A549细胞,培养-昼夜后,以30μM的终浓度在培养基中添加五味子素B。1小时后,除去培养基,照射3Gy的电离放射线,在含有与上述浓度相同的五味子素B的培养基中培养细胞1小时。对于该细胞,进行下述的组蛋白H3磷酸化量的测定。结果示于图3。各个数值与图2(B)相同。
(实施例4)经UV照射或电离放射线照射的A549细胞中五味子素B对p53磷酸化的影响
在增殖培养基中以3×104个/cm2的终浓度在10mm皿中接种A549细胞,培养一昼夜后,以30μM的终浓度在培养基中添加五味子素B。1小时后,除去培养基,照射20J/m2的UV,培养3小时(以下将这种细胞群称为UV细胞群)。
而且,同样,培养一昼夜,在培养基中以30μM的终浓度添加五味子素B,培养1小时,除去A549细胞的培养基,照射10Gy的电离放射线(γ射线),在含有与上述浓度相同的五味子素B的培养基中培养细胞2小时(以下将这种细胞群称为IR细胞群)。
而且,UV细胞群和IR细胞群中的任一者,从照射的15分钟前直至下述的细胞回收,都在50μm的N-乙酰基-L-亮氨酰-L-亮氨酰-正亮氨酸(N-acetyl-L-Leucyl-L-Leucyl-norleucinal,以下称为LLnL;Sigma公司制,MO,美国)存在下培养细胞。然后,按照下述的蛋白制备提取细胞中的蛋白质后,按照下述的免疫印迹分析,对p53蛋白的第15位的丝氨酸残基的磷酸化体(P-p53(Ser15))、p53蛋白(p53)、ATM蛋白的第1981位丝氨酸残基的磷酸化体(P-ATM(Ser1981))和甘油醛-3-磷酸脱氢酶(GAPDH),进行免疫印迹分析。结果示于图4。
(实施例5-1)经UV照射的A549细胞中五味子素B对p53磷酸化的浓度依赖性影响
在增殖培养基中以3×104个/cm2的终浓度在10mm皿中接种A549细胞,培养一昼夜后,以10、30和100μM的终浓度在培养基中添加五味子素B。1小时后,除去培养基,照射20J/m2的UV。并且,与实施例4相同,使用LLnL处理细胞。然后,按照下述免疫印迹用与上述同浓度的五味子素B处理1小时的细胞,研究p53和p53的第15位的丝氨酸残基的磷酸化体(P-p53(Ser15))的表达。结果示于图5-1。
(实施例5-2)
除了分别添加上述式(1)-(10)所示的化合物和上述式(C)所示的化合物(30μM的终浓度)来代替实施例5-1中在培养基中以30μM的终浓度添加五味子素B,照射25J/m2的UV替代20J/m2的UV之外,与实施例5-1相同进行,研究p53的第15位的丝氨酸残基的磷酸化体(P-p53(Ser15))的表达。此时获得的电泳图像示于图5-2,对于相当于P-p53(Ser15)的条带强度(用微管蛋白标准化的条带),以经UV照射获得的作为100%时的由各化合物获得的强度的相对比率示于表2。
表2
(实施例6)A549细胞中五味子素B对细胞周期的影响
在增殖培养基中以3×104个/cm2的终浓度在10mm皿中接种A549细胞,培养一昼夜后,以30μM的终浓度在培养基中添加五味子素B。4小时后,按照下述FACS分析,研究细胞周期。FACS分析的结果示于图6。
(实施例7-1)五味子素B产生的对ATR和ATM所具有的磷酸化活性的影响
在按照下述的磷酸化反应用ATR混合液和ATM混合液的制备获得的磷酸化反应用ATR混合液和ATM混合液中添加作为底物的1μg的重组PHAS-I蛋白质(Alexis Biochemicals公司制),与之同时添加五味子素B,添加具有适当浓度的32P-ATP的300μMATP,使之于30℃反应20分钟。用该反应液的4倍量的SDS加样缓冲液(200mMTris-HCl(pH6.8),400mMDTT和8%SDS)停止反应,将该混合液置于12%SDS-PAGE,将凝胶干燥后,对于与上述的混合液中的32P-ATP的条带,用自动放射照相法计算γ线剂量。结果示于图7。(A)和(B)分别表示ATR和ATM的相对活性,横轴表示五味子素B的浓度,纵轴以相对于不添加五味子素B的计算的相对值表示。
(实施例7-2)本发明的ATR抑制剂对ATR所具有的磷酸化活性的影响
除了使用上述式(1)-(5)所示的化合物和上述式(C)所示的化合物代替实施例7-1中的五味子素B之外,与实施例7-1相同进行,根据获得的直线计算IC50值。该值示于表3。
表3
(实施例8)经UV照射的AT2KY细胞中,五味子素B对各种蛋白的磷酸化的影响
以3×104个/cm2将AT2KY细胞(ヘルスサイエンス振兴财团(大阪))接种于含有15%FBS、100μg/mL链霉素和100个单位/mL青霉素的RPMI1640培养基中,培养一昼夜。在培养基中以30μM的终浓度添加五味子素B。添加1小时后,除去培养基,照射20J/cm2的UV。然后,对于用与上述浓度相同的五味子素B处理4小时的细胞,按照下述免疫印迹分析,研究p53的第15位的丝氨酸残基的磷酸化体(P-p53(Ser15))、Brca1的第1423位的丝氨酸残基的磷酸化体(P-Brca1(S1423))和Chk1的第345位的丝氨酸残基的磷酸化体(P-Chk1(S345))的表达。结果示于图8。
(实施例9)经抑制ATR或ATM表达的UV照射的A549细胞中,五味子素B对各种蛋白的磷酸化的影响
在增殖培养基中以3×104个/cm2的终浓度在10mm皿中接种A549细胞,培养一昼夜后,用Oligofectamine(Invitrogen公司制)和Opti-MEM(Invitrogen公司制),用按照下述siRNA的制备获得的各个双链siRNA(siGFP,siATM和siATR)转染细胞。培养一晚后,更换成新鲜的增殖培养基,72小时后,用30μM的五味子素B处理1小时,除去培养基,照射20J/m2的UV。然后,对于经与上述浓度相同的五味子素B处理3小时的细胞,按照下述免疫印迹,研究p53蛋白的第15位的丝氨酸残基的磷酸化体(P-p53(S15))、Chk1的第345位的丝氨酸残基的磷酸化体(P-Chk1(S345))、ATM蛋白(ATM)、ATM蛋白的第1981位丝氨酸残基的磷酸化体(P-ATM(Ser1981))和ATR蛋白(ATR)的表达。结果示于图9。而且,记载于图9中的P-p53(S15)和P-Chk1(S345)栏下的表达比率表示经对照siGFP和UV照射获得的各个蛋白的条带强度为1.0时各条带的相对强度。
(实施例10)A549细胞中,五味子素B对MAPK的磷酸化的影响
在增殖培养基中以3×104个/cm2的终浓度在10mm皿中接种A549细胞,培养一昼夜后,在无血清的增殖培养基中再培养16小时。然后,用50μMPD098059(Sigma公司制)或30μM五味子素B处理细胞,再用100ng/mLPhorbol-12-肉豆蔻酸13-醋酸(PMA;Sigma公司制)处理5分钟。然后,按照下述的免疫印迹分析,研究细胞的42kDa和44kDa促细胞分裂剂活性化蛋白质激酶(p42MAPK和p44MAPK)和它们的磷酸化体的表达。结果示于图10。
(组蛋白H3磷酸化量的测定)
用PBS清洗细胞后,用70%经冰冷却的乙醇固定。在其中添加含有0.25%Triton X-100的PBS,置于冰上30分钟后,回收细胞,离心分离(500G,5分钟),在获得的细胞小球中添加含有1%牛血清白蛋白(BSA)和1μg抗兔血清(特异于组蛋白H3的第13位的丝氨酸残基的磷酸化体)的PBS(100μL),室温下放置4小时。然后,用含有1%BSA的PBS将其清洗,添加用含有1%BSA的PBS稀释至100倍的结合了FITC的山羊抗兔IgG抗体,在黑暗的地方放置30分钟。再按照下述FACS分析进行PI染色后,用流式细胞仪(Beckman-Coulter公司制)测定磷酸化组蛋白H3量。
(免疫印迹分析)
对50μg的蛋白(按照下述的蛋白制备来制备的)进行SDS聚丙烯酰胺凝胶电泳(12.5%),按照常规方法将电泳后的各个蛋白转移到硝基纤维素膜上,用含有5%脱脂乳和0.1%Trion X-100的Tris缓冲生理盐水(TBS-T),室温下进行1小时封闭反应。用以下所示的所希望的抗体在4℃将获得的膜温育16小时,然后,用结合了来源于山萮菜的过氧化酶的二级抗血清(针对上述所希望的抗体的来源动物的)在室温下培养1小时。然后,用ECL反应试剂盒(Amersham公司制)和化学发光膜(Amersham公司制)使靶蛋白可视化,获得蛋白图像。
<抗体>
p53(Calbiochem公司制)
磷酸化p53抗体(Cell signaling technology公司制)
磷酸化ATM抗体(Rockland公司制)
磷酸化Chk1抗体(Cell signaling technology公司制)
ATR抗体(Bethyl公司制)
微管蛋白抗体(Sigma公司制)
GAPDH抗体(Santa Cruz公司制)
磷酸化Brca 1抗体(Upstate公司制)
抗MAPK抗体和抗磷酸化MAPK抗体(Cell Signaling公司制)
(蛋白制备)
用经冰冷却的PBS从培养皿中剥离细胞,用冷PBS清洗两次后,进行离心分离,在获得的细胞小球中用下述UTB缓冲液使之溶解,制备细胞来源的蛋白混合物。用蛋白质测试盒(Bio-Rad公司制,ProteinAssay Kit)测定蛋白量。
<UTB缓冲液>
8mM 尿素
150mM 2-巯基乙醇
50mM Tris(pH7.5)
(FACS分析)
用PBS清洗细胞后,用70%经冰冷却的乙醇固定。在通过离心分离回收的细胞小球中加入PBS清洗后,在进行离心分离。将细胞小球悬浮于含有终浓度为100μM的碘化丙锭(Propidium Iodide,Sigma公司,以下称为PI)和40μg/mL的RNaseA的溶液(PI溶液),在室温下培养30分钟。然后,用流式细胞仪(Beckman-Coulter公司制)分析细胞周期。
(磷酸化反应用ATR混合液和ATM混合液的制备)
在磷酸化反应用ATR混合液中,使用非专利文献9等公知的方法制备的经Flag标记的ATR。具体是,非专利文献9中公开的方法为将ATR基因(序列号4)的BamH1-SwaI片段(1kb)置换为对应于N末端具有Flag(DYKDDDDK)的ATR的基因,将通过PCR扩增的基因产物导入到pcDNA3.1中的质粒,从中合成经Flag标记的ATR。而且,在磷酸化反应用ATM混合液中,使用非专利文献10和11等公知的方法和快速改变定点诱变试剂盒(Quickchange Site-Directed Mutagenesis Kit,Stratagene公司制)制备的经Flag标记的ATM。
按照下述的磷酸钙法以这些经Flag标记的ATR和ATM质粒(序列号4和5)转染293T细胞(ATCC编号CRL-11268),培养两天。然后,于4℃4小时用20μg抗Flag-M2单克隆抗体I(Sigma公司制),使5mg按照将上述UTB缓冲液更换为下述的IP缓冲液进行的上述制备获得的蛋白混合物免疫沉淀。用结合了蛋白质G琼脂糖(Amersham公司制)的小珠与上述产物一起于4℃温育1小时。用下述TGN缓冲液清洗所获得的免疫复合体两次,再用下述激酶缓冲液清洗1次,获得磷酸化反应用ATR混合液和ATM混合液(序列号6和7)。
<IP缓冲液>
10mM Tris(pH7.5)
1mM EDTA
1mM EGTA
150mM NaCl
0.5% NP-40
1% Triton X-100
1mM 苯甲基磺酰氟化物(PMSF)
2μg/mL 胃酶抑素
2μg/mL 抑肽酶
1mM p,p’-二氯二苯三氯乙烷(DDT)
<TGN缓冲液>
50mM Tris(pH7.4)
50mM 磷酸甘油
150mM NaCl
1% Tween20
10% 甘油
<激酶缓冲液>
10mM Hepe s(pH7.5)
50mM 磷酸甘油
50mM NaCl
10mM MgCl2
10mM MnCl2
<磷酸钙法>
在增殖培养基中以2×104个/cm2的终浓度在10mm皿中接种293T细胞,培养一昼夜。然后,将上述Flag-ATM和Flag-ATR与终浓度为25mM的BES(N,N-二(2-羟基乙基)-2-氨基甲磺酸)和25mM的CaCl2混合,将其转染细胞。培养一晚后,更换成新鲜的增殖培养基,培养两天。
(siRNA的制备)
按照HP GenomeWide siRNA(QIAGEN公司制)合成针对ATR、ATM和绿色荧光蛋白(GFP)的双链siRNA(分别对应序列表中记载的序列号1、2和3)。将获得的双链siRNA分别命名为siATR、siATM和siGFP。
(考察)
ATM(毛细血管扩张性共济失调突变)和ATR(毛细血管扩张性共济失调和rad3相关的)在针对细胞周期的DNA损伤的反应中涉及的信号传递中扮演着重要的角色。ATM和ATR对Chk1、p53、NBS1、Brca1、SMC1等所有的关卡·蛋白质群和转录因子进行磷酸化。为了避免作为癌症发生成因的下一世代继续持有DNA损伤,上述关卡信号控制整个细胞周期。ATM或ATR的缺失,通过由UV或IR照射或抑制诱导性药剂诱导的DNA损伤,使细胞的存活率降低。这表明受到损伤的DNA的修复,维持和管理中需要ATM和ATR。在本发明中,本申请申请人公开了北五味子(Schisandra Chinensis)的成分的五味子素B使UV照射后的细胞的存活率以浓度依赖性显示下降。这表明体内的DNA损伤反应中,五味子素B对关卡信号途径具有抑制效果。
组蛋白H3,正常的分裂细胞中其第10位的丝氨酸残基被磷酸化,成为从G2期向M期移行的指标,但由于DNA损伤,G2期/M期关卡一旦行使功能,磷酸化组蛋白H3阳性细胞的比率就减少。如果根据图2,通过20和50J/m2的UV照射,磷酸化组蛋白H3的比率减少。另一方面,经50J/m2的UV照射并不明显,经20J/m2的UV照射,上式(1)所示的五味子素B使G2/M关卡显著崩溃。事实上,低剂量的UV照射中,对应于DNA损伤的反应中,五味子素B使G2/M关卡完全无效。而且,上式(1)-(10)所示的化合物和上式(C)所示的化合物和上式(C)所示的化合物也使G2/M关卡(checkpoint)完全无效。另一方面,对A549细胞进行IR照射时,不会引起G2/M关卡的剧烈抑制。已知,一般来说,IR照射使ATM活性化,UV照射使ATR活性化,使细胞周期关卡行使功能。根据这些结果显示,五味子素B在经低剂量的UV照射诱导的DNA损伤的过程中的G2/M关卡中,比起对ATM来说而是对ATR活性具有抑制效果。同样事项,也可以适用于上式(1)-(10)所示的化合物等本发明的ATR抑制剂的其它化合物。
为了验证本发明的ATR抑制剂对体内的ATR激酶活性的抑制活性,研究了经IR或UV照射诱导的DNA损伤后的p53磷酸化。已知p53在体内,在多个部位受到各种蛋白质激酶磷酸化,对于细胞来说是非常重要的转录因子。考虑癌症治疗中DNA损伤反应时的p53的功能时,细胞受到UV照射,γIR照射和甲基化剂的抑制时,p53的第15位的丝氨酸残基中,被ATR和ATM特异性磷酸化。本发明中,对A549细胞进行20J/m2的UV照射后,p53磷酸化由于五味子素B而减少,经IR照射并未减少。IR照射后ATM的第1981位的丝氨酸残基被显著活性化,而经20J/m2的UV照射仅少量被活性化,而五味子素B在任意一种DNA损伤中,对ATM活性都不产生影响。而且,也没有发现五味子素B所产生的细胞周期的局部的积累和偏向。而且,观察到了上式(1)-(10)所示的化合物对p53磷酸化的抑制。根据这些结果,表明经20J/m2的UV照射所产生的p53的第15位的丝氨酸残基的磷酸化的减少只由ATR引起。
非专利文献7公开了咖啡因对于A549腺癌细胞中ATM和ATR蛋白激酶的抑制效果。本申请申请人通过与该文献相同的方法,研究了在体外五味子素B对ATM和ATR的蛋白质激酶活性的影响。如果将五味子素B与激酶缓冲液一起温育,就会抑制ATM和ATR,五味子素B抑制ATR蛋白质激酶比抑制ATM更为显著。事实上,五味子素B产生的对ATR的IC50是ATM的约240倍。而且,观察到上式(1)-(5)所示化合物显著抑制ATR蛋白质激酶活性。细胞的存活率和激酶活性的结果表示,诱导细胞的DNA损伤的UV照射的反应中,ATR蛋白质激酶活性受到抑制。
为了研究五味子素B对DNA损伤所涉及的关卡的影响,使用AT患者来源的成纤维细胞(AT2KY)和siRNA处理细胞。如果对AT2KY进行UV照射,不仅磷酸化p53以及关卡途径中ATM和ATR的作为下游分子的Brca1(Ser1423)和Chk1(Ser345)的磷酸化体就增加。而且,只是在对照和ATM所涉及的经siRNA处理的细胞中,五味子素B使p53和Chk1的磷酸化减少。而且,经siRNA处理的细胞中,并没有观察到关卡的蛋白质所涉及的磷酸化有所减少。根据这些结果,表明五味子素B在体内介导ATR蛋白质激酶活性的抑制,抑制DNA损伤所涉及的关卡的信号传递途径。
为了确认五味子素B在体内对ATR抑制的特异性,研究了称为促细胞分裂剂活性化蛋白质激酶(MAPK)的ERK的血清刺激和PMA处理对由特异的活性化系统所产生的磷酸化的效果。ERK的磷酸化,通过上述的参照方法,受到强力促进。该ERK磷酸化完全不受五味子素B的影响。因此清楚了,针对DNA损伤的反应中,五味子素B的有效性高度特异于ATR活性。
在本发明中,通过对细胞的UV照射诱导的DNA损伤应答反应(关卡)中出现五味子素B的效果。由于敲除了ATR的胚细胞是致死的,因此预测ATR在哺乳类成长的阶段扮演着重要的角色。这表明染色质的不稳定化,对应于生物体内连续生成的自由基的关卡的缺失,和生长过程中的细胞性DNA的复制压力所产生的关卡中需要ATR。另一方面,由于ATR起ATM的后备的作用,因此关卡在AT患者来源的细胞(遗传上ATM不起作用的细胞)中维持关卡。这表明,包括肿瘤发生的增殖性细胞中,ATR蛋白质激酶十分重要。由于可以通过ATR的激酶活性抑制阻止患者中DNA损伤关卡,因此根据本发明的见解,五味子素B在放射线疗法和化学疗法等的抗癌治疗中可具有优势。咖啡因,与ATR相比,具有1/5的IC50的ATM的活性。因此,可以预见在临床中癌症治疗时,如果五味子素B单独或与咖啡因组合进行放射线疗法和化学疗法,它们的感受性会显著增加。
非专利文献3报告了在临床中试验性地使用咖啡因作为化疗剂或放射线治疗的辅助。该文献公开了,通过由咖啡因辅助的治疗,与分别处理化疗剂或放射线疗法相比,骨肉瘤的尺寸减少且最小化。这些结果表明,咖啡因抑制ATM和ATR蛋白质激酶活性,在增殖肿瘤的细胞周期的任一阶段,也都会带来对DNA损伤所涉及的关卡的抑制。因此,作为由五味子素B辅助的化学疗法和放射线疗法,五味子素B存在临床试验性应用的可能性。进一步研究所涉及的,对于在咖啡因的临床试验的同时使肿瘤消失或使之最小化所涉及的效率化是否可能,需要研究与五味子素B一起使用的效果。尤其是,五味子素B,为希望是在患者中完全没有副作用的天然植物体取物中的成分。即使化疗/放射线疗法的给药量和剂量降低至最低限度,可预计上述这种ATM/ATR抑制剂具有与以往相同或其之上的效果,因此对于化疗/放射线疗法,通过组合五味子素B和咖啡因,可以预计将对患者的副作用抑制到最小限度。
以上,通过本发明的优选的实施方式对本发明进行了说明。其中,公开了特定的具体例子说明本发明,但是清楚的是,不脱离权利要求的范围中定义的本发明的广泛的目的和范围,可以对这些具体例子增加各种修正和改变。即,本发明不受具体例子的详细内容和添加的附图限定和解释。
序列表
<110>Niigata TLO Corporation
<120>ATR inhibitor
<130>D-18646
<160>7
<170>PatentIn version 3.3
<210>1
<211>21
<212>DNA
<213>Synthetic
<400>1
aagcgcctga ttcgagatcc t 21
<210>2
<211>21
<212>DNA
<213>Synthetic
<400>2
aagacggtgt gctcatgcgg c 21
<210>3
<211>24
<212>DNA
<213>Synthetic
<400>3
cggcaagctg accctgaagt tcat 24
<210>4
<211>8265
<212>DNA
<213>Synthetic
<400>4
gcctccacac ggctccgtcg ggcgccgcgc tcttccggca gcggtacgtt tggagacgcc 60
gggaacccgc gttggcgtgg ttgactagtg cctcgcagcc tcagcatggg ggaacatggc 120
ctggagctgg cttccatgat ccccgccctg cgggagctgg gcagtgccac accagaggaa 180
tataatacag ttgtacagaa gccaagacaa attctgtgtc aattcattga ccggatactt 240
acagatgtaa atgttgttgc tgtagaactt gtaaagaaaa ctgactctca gccaacctcc 300
gtgatgttgc ttgatttcat ccagcatatc atgaaatcct ccccacttat gtttgtaaat 360
gtgagtggaa gccatgagcg caaaggcagt tgtattgaat tcagtaattg gatcataacg 420
agacttctgc ggattgcagc aactccctcc tgtcatttgt tacacaagaa aatctgtgaa 480
gtcatctgtt cattattatt tctttttaaa agcaagagtc ctgctatttt tggggtactc 540
acaaaagaat tattacaact ttttgaagac ttggtttacc tccatagaag aaatgtgatg 600
ggtcatgctg tggaatggcc agtggtcatg agccgatttt taagtcaatt agatgaacac 660
atgggatatt tacaatcagc tcctttgcag ttgatgagta tgcaaaattt agaatttatt 720
gaagtcactt tattaatggt tcttactcgt attattgcaa ttgtgttttt tagaaggcaa 780
gaactcttac tttggcagat aggttgtgtt ctgctagagt atggtagtcc aaaaattaaa 840
tccctagcaa ttagcttttt aacagaactt tttcagcttg gaggactacc agcacaacca 900
gctagcactt ttttcagctc atttttggaa ttattaaaac accttgtaga aatggatact 960
gaccaattga aactctatga agagccatta tcaaagctga taaagacact atttcccttt 1020
gaagcagaag cttatagaaa tattgaacct gtctatttaa atatgctgct ggaaaaactc 1080
tgtgtcatgt ttgaagacgg tgtgctcatg cggcttaagt ctgatttgct aaaagcagct 1140
ttgtgccatt tactgcagta tttccttaaa tttgtgccag ctgggtatga atctgcttta 1200
caagtcagga aggtctatgt gagaaatatt tgtaaagctc ttttggatgt gcttggaatt 1260
gaggtagatg cagagtactt gttgggccca ctttatgcag ctttgaaaat ggaaagtatg 1320
gaaatcattg aggagattca atgccaaact caacaggaaa acctcagcag taatagtgat 1380
ggaatatcac ccaaaaggcg tcgtctcagc tcgtctctaa acccttctaa aagagcacca 1440
aaacagactg aggaaattaa acatgtggac atgaaccaaa agagcatatt atggagtgca 1500
ctgaaacaga aagctgaatc ccttcagatt tcccttgaat acagtggcct aaagaatcct 1560
gttattgaga tgttagaagg aattgctgtt gtcttacaac tgactgctct gtgtactgtt 1620
cattgttctc atcaaaacat gaactgccgt actttcaagg actgtcaaca taaatccaag 1680
aagaaacctt ctgtagtgat aacttggatg tcattggatt tttacacaaa agtgcttaag 1740
agctgtagaa gtttgttaga atctgttcag aaactggacc tggaggcaac cattgataag 1800
gtggtgaaaa tttatgatgc tttgatttat atgcaagtaa acagttcatt tgaagatcat 1860
atcctggaag atttatgtgg tatgctctca cttccatgga tttattccca ttctgatgat 1920
ggctgtttaa agttgaccac atttgccgct aatcttctaa cattaagctg taggatttca 1980
gatagctatt caccacaggc acaatcacga tgtgtgtttc ttctgactct gtttccaaga 2040
agaatattcc ttgagtggag aacagcagtt tacaactggg ccctgcagag ctcccatgaa 2100
gtaatccggg ctagttgtgt tagtggattt tttatcttat tgcagcagca gaattcttgt 2160
aacagagttc ccaagattct tatagataaa gtcaaagatg attctgacat tgtcaagaaa 2220
gaatttgctt ctatacttgg tcaacttgtc tgtactcttc acggcatgtt ttatctgaca 2280
agttctttaa cagaaccttt ctctgaacac ggacatgtgg acctcttctg taggaacttg 2340
aaagccactt ctcaacatga atgttcatct tctcaactaa aagcttctgt ctgcaagcca 2400
ttccttttcc tactgaaaaa aaaaatacct agtccagtaa aacttgcttt catagataat 2460
ctacatcatc tttgtaagca tcttgatttt agagaagatg aaacagatgt aaaagcagtt 2520
cttggaactt tattaaattt aatggaagat ccagacaaag atgttagagt ggcttttagt 2580
ggaaatatca agcacatatt ggaatccttg gactctgaag atggatttat aaaggagctt 2640
tttgtcttaa gaatgaagga agcatataca catgcccaaa tatcaagaaa taatgagctg 2700
aaggatacct tgattcttac aacaggggat attggaaggg ccgcaaaagg agatttggta 2760
ccatttgcac tcttacactt attgcattgt ttgttatcca agtcagcatc tgtctctgga 2820
gcagcataca cagaaattag agctctggtt gcagctaaaa gtgttaaact gcaaagtttt 2880
ttcagccagt ataagaaacc catctgtcag tttttggtag aatcccttca ctctagtcag 2940
atgacagcac ttccgaatac tccatgccag aatgctgacg tgcgaaaaca agatgtggct 3000
caccagagag aaatggcttt aaatacgttg tctgaaattg ccaacgtttt cgactttcct 3060
gatcttaatc gttttcttac taggacatta caagttctac tacctgatct tgctgccaaa 3120
gcaagccctg cagcttctgc tctcattcga actttaggaa aacaattaaa tgtcaatcgt 3180
agagagattt taataaacaa cttcaaatat attttttctc atttggtctg ttcttgttcc 3240
aaagatgaat tagaacgtgc ccttcattat ctgaagaatg aaacagaaat tgaactgggg 3300
agcctgttga gacaagattt ccaaggattg cataatgaat tattgctgcg tattggagaa 3360
cactatcaac aggtttttaa tggtttgtca atacttgcct catttgcatc cagtgatgat 3420
ccatatcagg gcccgagaga tatcatatca cctgaactga tggctgatta tttacaaccc 3480
aaattgttgg gcattttggc tttttttaac atgcagttac tgagctctag tgttggcatt 3540
gaagataaga aaatggcctt gaacagtttg atgtctttga tgaagttaat gggacccaaa 3600
catgtcagtt ctgtgagggt gaagatgatg accacactga gaactggcct tcgattcaag 3660
gatgattttc ctgaattgtg ttgcagagct tgggactgct ttgttcgctg cctggatcat 3720
gcttgtctgg gctcccttct cagtcatgta atagtagctt tgttacctct tatacacatc 3780
cagcctaaag aaactgcagc tatcttccac tacctcataa ttgaaaacag ggatgctgtg 3840
caagattttc ttcatgaaat atatttttta cctgatcatc cagaattaaa aaagataaaa 3900
gccgttctcc aggaatacag aaaggagacc tctgagagca ctgatcttca gacaactctt 3960
cagctctcta tgaaggccat tcaacatgaa aatgtcgatg ttcgtattca tgctcttaca 4020
agcttgaagg aaaccttgta taaaaatcag gaaaaactga taaagtatgc aacagacagt 4080
gaaacagtag aacctattat ctcacagttg gtgacagtgc ttttgaaagg ttgccaagat 4140
gcaaactctc aagctcggtt gctctgtggg gaatgtttag gggaattggg ggcgatagat 4200
ccaggtcgat tagatttctc aacaactgaa actcaaggaa aagattttac atttgtgact 4260
ggagtagaag attcaagctt tgcctatgga ttattgatgg agctaacaag agcttacctt 4320
gcgtatgctg ataatagccg agctcaagat tcagctgcct atgccattca ggagttgctt 4380
tctatttatg actgtagaga gatggagacc aacggcccag gtcaccaatt gtggaggaga 4440
tttcctgagc atgttcggga aatactagaa cctcatctaa ataccagata caagagttct 4500
cagaagtcaa ccgattggtc tggagtaaag aagccaattt acttaagtaa attgggtagt 4560
aactttgcag aatggtcagc atcttgggca ggttatctta ttacaaaggt tcgacatgat 4620
cttgccagta aaattttcac ctgctgtagc attatgatga agcatgattt caaagtgacc 4680
atctatcttc ttccacatat tctggtgtat gtcttactgg gttgtaatca agaagatcag 4740
caggaggttt atgcagaaat tatggcagtt ctaaagcatg acgatcagca taccataaat 4800
acccaagaca ttgcatctga tctgtgtcaa ctcagtacac agactgtgtt ctccatgctt 4860
gaccatctca cacagtgggc aaggcacaaa tttcaggcac tgaaagctga gaaatgtcca 4920
cacagcaaat caaacagaaa taaggtagac tcaatggtat ctactgtgga ttatgaagac 4980
tatcagagtg taacccgttt tctagacctc ataccccagg atactctggc agtagcttcc 5040
tttcgctcca aagcatacac acgagctgta atgcactttg aatcatttat tacagaaaag 5100
aagcaaaata ttcaggaaca tcttggattt ttacagaaat tgtatgctgc tatgcatgaa 5160
cctgatggag tggccggagt cagtgcaatt agaaaggcag aaccatctct aaaagaacag 5220
atccttgaac atgaaagcct tggcttgctg agggatgcca ctgcttgtta tgacagggct 5280
attcagctag aaccagacca gatcattcat tatcatggtg tagtaaagtc catgttaggt 5340
cttggtcagc tgtctactgt tatcactcag gtgaatggag tgcatgctaa caggtccgag 5400
tggacagatg aattaaacac gtacagagtg gaagcagctt ggaaattgtc acagtgggat 5460
ttggtggaaa actatttggc agcagatgga aaatctacaa catggagtgt cagactggga 5520
cagctattat tatcagccaa aaaaagagat atcacagctt tttatgactc actgaaacta 5580
gtgagagcag aacaaattgt acctctttca gctgcaagct ttgaaagagg ctcctaccaa 5640
cgaggatatg aatatattgt gagattgcac atgttatgtg agttggagca tagcatcaaa 5700
ccacttttcc agcattctcc aggtgacagt tctcaagaag attctctaaa ctgggtagct 5760
cgactagaaa tgacccagaa ttcctacaga gccaaggagc ctatcctggc tctccggagg 5820
gctttactaa gcctcaacaa aagaccagat tacaatgaaa tggttggaga atgctggctg 5880
cagagtgcca gggtagctag aaaggctggt caccaccaga cagcctacaa tgctctcctt 5940
aatgcagggg aatcacgact cgctgaactg tacgtggaaa gggcaaagtg gctctggtcc 6000
aagggtgatg ttcaccaggc actaattgtt cttcaaaaag gtgttgaatt atgttttcct 6060
gaaaatgaaa ccccacctga gggtaagaac atgttaatcc atggtcgagc tatgctacta 6120
gtgggccgat ttatggaaga aacagctaac tttgaaagca atgcaattat gaaaaaatat 6180
aaggatgtga ccgcgtgcct gccagaatgg gaggatgggc atttttacct tgccaagtac 6240
tatgacaaat tgatgcccat ggtcacagac aacaaaatgg aaaagcaagg tgatctcatc 6300
cggtatatag ttcttcattt tggcagatct ctacaatatg gaaatcagtt catatatcag 6360
tcaatgccac gaatgttaac tctatggctt gattatggta caaaggcata tgaatgggaa 6420
aaagctggcc gctccgatcg tgtacaaatg aggaatgatt tgggtaaaat aaacaaggtt 6480
atcacagagc atacaaacta tttagctcca tatcaatttt tgactgcttt ttcacaattg 6540
atctctcgaa tttgtcattc tcacgatgaa gtttttgttg tcttgatgga aataatagcc 6600
aaagtatttc tagcctatcc tcaacaagca atgtggatga tgacagctgt gtcaaagtca 6660
tcttatccca tgcgtgtgaa cagatgcaag gaaatcctca ataaagctat tcatatgaaa 6720
aaatccttag agaagtttgt tggagatgca actcgcctaa cagataagct tctagaattg 6780
tgcaataaac cggttgatgg aagtagttcc acattaagca tgagcactca ttttaaaatg 6840
cttaaaaagc tggtagaaga agcaacattt agtgaaatcc tcattcctct acaatcagtc 6900
atgataccta cacttccatc aattctgggt acccatgcta accatgctag ccatgaacca 6960
tttcctggac attgggccta tattgcaggg tttgatgata tggtggaaat tcttgcttct 7020
cttcagaaac caaagaagat ttctttaaaa ggctcagatg gaaagttcta catcatgatg 7080
tgtaagccaa aagatgacct gagaaaggat tgtagactaa tggaattcaa ttccttgatt 7140
aataagtgct taagaaaaga tgcagagtct cgtagaagag aacttcatat tcgaacatat 7200
gcagttattc cactaaatga tgaatgtggg attattgaat gggtgaacaa cactgctggt 7260
ttgagaccta ttctgaccaa actatataaa gaaaagggag tgtatatgac aggaaaagaa 7320
cttcgccagt gtatgctacc aaagtcagca gctttatctg aaaaactcaa agtattccga 7380
gaatttctcc tgcccaggca tcctcctatt tttcatgagt ggtttctgag aacattccct 7440
gatcctacat catggtacag tagtagatca gcttactgcc gttccactgc agtaatgtca 7500
atggttggtt atattctggg gcttggagac cgtcatggtg aaaatattct ctttgattct 7560
ttgactggtg aatgcgtaca tgtagatttc aattgtcttt tcaataaggg agaaaccttt 7620
gaagttccag aaattgtgcc atttcgcctg actcataata tggttaatgg aatgggtcct 7680
atgggaacag agggtctttt tcgaagagca tgtgaagtta caatgaggct gatgcgtgat 7740
cagcgagagc ctttaatgag tgtcttaaag acttttctac atgatcctct tgtggaatgg 7800
agtaaaccag tgaaagggca ttccaaagcg ccactgaatg aaactggaga agttgtcaat 7860
gaaaaggcca agacccatgt tcttgacatt gagcagcgac tacaaggtgt aatcaagact 7920
cgaaatagag tgacaggact gccgttatct attgaaggac atgtgcatta ccttatacaa 7980
gaagctactg atgaaaactt actatgccag atgtatcttg gttggactcc atatatgtga 8040
aatgaaatta tgtaaaagaa tatgttaata atctaaaagt aatgcatttg gtatgaatct 8100
gtggttgtat ctgttcaatt ctaaagtaca acataaattt acgttctcag caactgttat 8160
ttctctctga tcattaatta tatgtaaaat aatatacatt cagttattaa gaaataaact 8220
gctttcttaa taaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaa 8265
<210>5
<211>13147
<212>DNA
<213>Homo sapiens
<400>5
ccggagcccg agccgaaggg cgagccgcaa acgctaagtc gctggccatt ggtggacatg 60
gcgcaggcgc gtttgctccg acgggccgaa tgttttgggg cagtgttttg agcgcggaga 120
ccgcgtgata ctggatgcgc atgggcatac cgtgctctgc ggctgcttgg cgttgcttct 180
tcctccagaa gtgggcgctg ggcagtcacg cagggtttga accggaagcg ggagtaggta 240
gctgcgtggc taacggagaa aagaagccgt ggccgcggga ggaggcgaga ggagtcggga 300
tctgcgctgc agccaccgcc gcggttgata ctactttgac cttccgagtg cagtgacagt 360
gatgtgtgtt ctgaaattgt gaaccatgag tctagtactt aatgatctgc ttatctgctg 420
ccgtcaacta gaacatgata gagctacaga acgaaagaaa gaagttgaga aatttaagcg 480
cctgattcga gatcctgaaa caattaaaca tctagatcgg cattcagatt ccaaacaagg 540
aaaatatttg aattgggatg ctgtttttag atttttacag aaatatattc agaaagaaac 600
agaatgtctg agaatagcaa aaccaaatgt atcagcctca acacaagcct ccaggcagaa 660
aaagatgcag gaaatcagta gtttggtcaa atacttcatc aaatgtgcaa acagaagagc 720
acctaggcta aaatgtcaag aactcttaaa ttatatcatg gatacagtga aagattcatc 780
taatggtgct atttacggag ctgattgtag caacatacta ctcaaagaca ttctttctgt 840
gagaaaatac tggtgtgaaa tatctcagca acagtggtta gaattgttct ctgtgtactt 900
caggctctat ctgaaacctt cacaagatgt tcatagagtt ttagtggcta gaataattca 960
tgctgttacc aaaggatgct gttctcagac tgacggatta aattccaaat ttttggactt 1020
tttttccaag gctattcagt gtgcgagaca agaaaagagc tcttcaggtc taaatcatat 1080
cttagcagct cttactatct tcctcaagac tttggctgtc aactttcgaa ttcgagtgtg 1140
tgaattagga gatgaaattc ttcccacttt gctttatatt tggactcaac ataggcttaa 1200
tgattcttta aaagaagtca ttattgaatt atttcaactg caaatttata tccatcatcc 1260
gaaaggagcc aaaacccaag aaaaaggtgc ttatgaatca acaaaatgga gaagtatttt 1320
atacaactta tatgatctgc tagtgaatga gataagtcat ataggaagta gaggaaagta 1380
ttcttcagga tttcgtaata ttgccgtcaa agaaaatttg attgaattga tggcagatat 1440
ctgtcaccag gtttttaatg aagataccag atccttggag atttctcaat cttacactac 1500
tacacaaaga gaatctagtg attacagtgt cccttgcaaa aggaagaaaa tagaactagg 1560
ctgggaagta ataaaagatc accttcagaa gtcacagaat gattttgatc ttgtgccttg 1620
gctacagatt gcaacccaat taatatcaaa gtatcctgca agtttaccta actgtgagct 1680
gtctccatta ctgatgatac tatctcagct tctaccccaa cagcgacatg gggaacgtac 1740
accatatgtg ttacgatgcc ttacggaagt tgcattgtgt caagacaaga ggtcaaacct 1800
agaaagctca caaaagtcag atttattaaa actctggaat aaaatttggt gtattacctt 1860
tcgtggtata agttctgagc aaatacaagc tgaaaacttt ggcttacttg gagccataat 1920
tcagggtagt ttagttgagg ttgacagaga attctggaag ttatttactg ggtcagcctg 1980
cagaccttca tgtcctgcag tatgctgttt gactttggca ctgaccacca gtatagttcc 2040
aggaacggta aaaatgggaa tagagcaaaa tatgtgtgaa gtaaatagaa gcttttcttt 2100
aaaggaatca ataatgaaat ggctcttatt ctatcagtta gagggtgact tagaaaatag 2160
cacagaagtg cctccaattc ttcacagtaa ttttcctcat cttgtactgg agaaaattct 2220
tgtgagtctc actatgaaaa actgtaaagc tgcaatgaat tttttccaaa gcgtgccaga 2280
atgtgaacac caccaaaaag ataaagaaga actttcattc tcagaagtag aagaactatt 2340
tcttcagaca acttttgaca agatggactt tttaaccatt gtgagagaat gtggtataga 2400
aaagcaccag tccagtattg gcttctctgt ccaccagaat ctcaaggaat cactggatcg 2460
ctgtcttctg ggattatcag aacagcttct gaataattac tcatctgaga ttacaaattc 2520
agaaactctt gtccggtgtt cacgtctttt ggtgggtgtc cttggctgct actgttacat 2580
gggtgtaata gctgaagagg aagcatataa gtcagaatta ttccagaaag ccaagtctct 2640
aatgcaatgt gcaggagaaa gtatcactct gtttaaaaat aagacaaatg aggaattcag 2700
aattggttcc ttgagaaata tgatgcagct atgtacacgt tgcttgagca actgtaccaa 2760
gaagagtcca aataagattg catctggctt tttcctgcga ttgttaacat caaagctaat 2820
gaatgacatt gcagatattt gtaaaagttt agcatccttc atcaaaaagc catttgaccg 2880
tggagaagta gaatcaatgg aagatgatac taatggaaat ctaatggagg tggaggatca 2940
gtcatccatg aatctattta acgattaccc tgatagtagt gttagtgatg caaacgaacc 3000
tggagagagc caaagtacca taggtgccat taatccttta gctgaagaat atctgtcaaa 3060
gcaagatcta cttttcttag acatgctcaa gttcttgtgt ttgtgtgtaa ctactgctca 3120
gaccaatact gtgtccttta gggcagctga tattcggagg aaattgttaa tgttaattga 3180
ttctagcacg ctagaaccta ccaaatccct ccacctgcat atgtatctaa tgcttttaaa 3240
ggagcttcct ggagaagagt accccttgcc aatggaagat gttcttgaac ttctgaaacc 3300
actatccaat gtgtgttctt tgtatcgtcg tgaccaagat gtttgtaaaa ctattttaaa 3360
ccatgtcctt catgtagtga aaaacctagg tcaaagcaat atggactctg agaacacaag 3420
ggatgctcaa ggacagtttc ttacagtaat tggagcattt tggcatctaa caaaggagag 3480
gaaatatata ttctctgtaa gaatggccct agtaaattgc cttaaaactt tgcttgaggc 3540
tgatccttat tcaaaatggg ccattcttaa tgtaatggga aaagactttc ctgtaaatga 3600
agtatttaca caatttcttg ctgacaatca tcaccaagtt cgcatgttgg ctgcagagtc 3660
aatcaataga ttgttccagg acacgaaggg agattcttcc aggttactga aagcacttcc 3720
tttgaagctt cagcaaacag cttttgaaaa tgcatacttg aaagctcagg aaggaatgag 3780
agaaatgtcc catagtgctg agaaccctga aactttggat gaaatttata atagaaaatc 3840
tgttttactg acgttgatag ctgtggtttt atcctgtagc cctatctgcg aaaaacaggc 3900
tttgtttgcc ctgtgtaaat ctgtgaaaga gaatggatta gaacctcacc ttgtgaaaaa 3960
ggttttagag aaagtttctg aaacttttgg atatagacgt ttagaagact ttatggcatc 4020
tcatttagat tatctggttt tggaatggct aaatcttcaa gatactgaat acaacttatc 4080
ttcttttcct tttattttat taaactacac aaatattgag gatttctata gatcttgtta 4140
taaggttttg attccacatc tggtgattag aagtcatttt gatgaggtga agtccattgc 4200
taatcagatt caagaggact ggaaaagtct tctaacagac tgctttccaa agattcttgt 4260
aaatattctt ccttattttg cctatgaggg taccagagac agtgggatgg cacagcaaag 4320
agagactgct accaaggtct atgatatgct taaaagtgaa aacttattgg gaaaacagat 4380
tgatcactta ttcattagta atttaccaga gattgtggtg gagttattga tgacgttaca 4440
tgagccagca aattctagtg ccagtcagag cactgacctc tgtgactttt caggggattt 4500
ggatcctgct cctaatccac ctcattttcc atcgcatgtg attaaagcaa catttgccta 4560
tatcagcaat tgtcataaaa ccaagttaaa aagcatttta gaaattcttt ccaaaagccc 4620
tgattcctat cagaaaattc ttcttgccat atgtgagcaa gcagctgaaa caaataatgt 4680
ttataagaag cacagaattc ttaaaatata tcacctgttt gttagtttat tactgaaaga 4740
tataaaaagt ggcttaggag gagcttgggc ctttgttctt cgagacgtta tttatacttt 4800
gattcactat atcaaccaaa ggccttcttg tatcatggat gtgtcattac gtagcttctc 4860
cctttgttgt gacttattaa gtcaggtttg ccagacagcc gtgacttact gtaaggatgc 4920
tctagaaaac catcttcatg ttattgttgg tacacttata ccccttgtgt atgagcaggt 4980
ggaggttcag aaacaggtat tggacttgtt gaaatactta gtgatagata acaaggataa 5040
tgaaaacctc tatatcacga ttaagctttt agatcctttt cctgaccatg ttgtttttaa 5100
ggatttgcgt attactcagc aaaaaatcaa atacagtaga ggaccctttt cactcttgga 5160
ggaaattaac cattttctct cagtaagtgt ttatgatgca cttccattga caagacttga 5220
aggactaaag gatcttcgaa gacaactgga actacataaa gatcagatgg tggacattat 5280
gagagcttct caggataatc cgcaagatgg gattatggtg aaactagttg tcaatttgtt 5340
gcagttatcc aagatggcaa taaaccacac tggtgaaaaa gaagttctag aggctgttgg 5400
aagctgcttg ggagaagtgg gtcctataga tttctctacc atagctatac aacatagtaa 5460
agatgcatct tataccaagg cccttaagtt atttgaagat aaagaacttc agtggacctt 5520
cataatgctg acctacctga ataacacact ggtagaagat tgtgtcaaag ttcgatcagc 5580
agctgttacc tgtttgaaaa acattttagc cacaaagact ggacatagtt tctgggagat 5640
ttataagatg acaacagatc caatgctggc ctatctacag ccttttagaa catcaagaaa 5700
aaagttttta gaagtaccca gatttgacaa agaaaaccct tttgaaggcc tggatgatat 5760
aaatctgtgg attcctctaa gtgaaaatca tgacatttgg ataaagacac tgacttgtgc 5820
ttttttggac agtggaggca caaaatgtga aattcttcaa ttattaaagc caatgtgtga 5880
agtgaaaact gacttttgtc agactgtact tccatacttg attcatgata ttttactcca 5940
agatacaaat gaatcatgga gaaatctgct ttctacacat gttcagggat ttttcaccag 6000
ctgtcttcga cacttctcgc aaacgagccg atccacaacc cctgcaaact tggattcaga 6060
gtcagagcac tttttccgat gctgtttgga taaaaaatca caaagaacaa tgcttgctgt 6120
tgtggactac atgagaagac aaaagagacc ttcttcagga acaattttta atgatgcttt 6180
ctggctggat ttaaattatc tagaagttgc caaggtagct cagtcttgtg ctgctcactt 6240
tacagcttta ctctatgcag aaatctatgc agataagaaa agtatggatg atcaagagaa 6300
aagaagtctt gcatttgaag aaggaagcca gagtacaact atttctagct tgagtgaaaa 6360
aagtaaagaa gaaactggaa taagtttaca ggatcttctc ttagaaatct acagaagtat 6420
aggggagcca gatagtttgt atggctgtgg tggagggaag atgttacaac ccattactag 6480
actacgaaca tatgaacacg aagcaatgtg gggcaaagcc ctagtaacat atgacctcga 6540
aacagcaatc ccctcatcaa cacgccaggc aggaatcatt caggccttgc agaatttggg 6600
actctgccat attctttccg tctatttaaa aggattggat tatgaaaata aagactggtg 6660
tcctgaacta gaagaacttc attaccaagc agcatggagg aatatgcagt gggaccattg 6720
cacttccgtc agcaaagaag tagaaggaac cagttaccat gaatcattgt acaatgctct 6780
acaatctcta agagacagag aattctctac attttatgaa agtctcaaat atgccagagt 6840
aaaagaagtg gaagagatgt gtaagcgcag ccttgagtct gtgtattcgc tctatcccac 6900
acttagcagg ttgcaggcca ttggagagct ggaaagcatt ggggagcttt tctcaagatc 6960
agtcacacat agacaactct ctgaagtata tattaagtgg cagaaacact cccagcttct 7020
caaggacagt gattttagtt ttcaggagcc tatcatggct ctacgcacag tcattttgga 7080
gatcctgatg gaaaaggaaa tggacaactc acaaagagaa tgtattaagg acattctcac 7140
caaacacctt gtagaactct ctatactggc cagaactttc aagaacactc agctccctga 7200
aagggcaata tttcaaatta aacagtacaa ttcagttagc tgtggagtct ctgagtggca 7260
gctggaagaa gcacaagtat tctgggcaaa aaaggagcag agtcttgccc tgagtattct 7320
caagcaaatg atcaagaagt tggatgccag ctgtgcagcg aacaatccca gcctaaaact 7380
tacatacaca gaatgtctga gggtttgtgg caactggtta gcagaaacgt gcttagaaaa 7440
tcctgcggtc atcatgcaga cctatctaga aaaggcagta gaagttgctg gaaattatga 7500
tggagaaagt agtgatgagc taagaaatgg aaaaatgaag gcatttctct cattagcccg 7560
gttttcagat actcaatacc aaagaattga aaactacatg aaatcatcgg aatttgaaaa 7620
caagcaagct ctcctgaaaa gagccaaaga ggaagtaggt ctccttaggg aacataaaat 7680
tcagacaaac agatacacag taaaggttca gcgagagctg gagttggatg aattagccct 7740
gcgtgcactg aaagaggatc gtaaacgctt cttatgtaaa gcagttgaaa attatatcaa 7800
ctgcttatta agtggagaag aacatgatat gtgggtattc cgactttgtt ccctctggct 7860
tgaaaattct ggagtttctg aagtcaatgg catgatgaag agagacggaa tgaagattcc 7920
aacatataaa tttttgcctc ttatgtacca attggctgct agaatgggga ccaagatgat 7980
gggaggccta ggatttcatg aagtcctcaa taatctaatc tctagaattt caatggatca 8040
cccccatcac actttgttta ttatactggc cttagcaaat gcaaacagag atgaatttct 8100
gactaaacca gaggtagcca gaagaagcag aataactaaa aatgtgccta aacaaagctc 8160
tcagcttgat gaggatcgaa cagaggctgc aaatagaata atatgtacta tcagaagtag 8220
gagacctcag atggtcagaa gtgttgaggc actttgtgat gcttatatta tattagcaaa 8280
cttagatgcc actcagtgga agactcagag aaaaggcata aatattccag cagaccagcc 8340
aattactaaa cttaagaatt tagaagatgt tgttgtccct actatggaaa ttaaggtgga 8400
ccacacagga gaatatggaa atctggtgac tatacagtca tttaaagcag aatttcgctt 8460
agcaggaggt gtaaatttac caaaaataat agattgtgta ggttccgatg gcaaggagag 8520
gagacagctt gttaagggcc gtgatgacct gagacaagat gctgtcatgc aacaggtctt 8580
ccagatgtgt aatacattac tgcagagaaa cacggaaact aggaagagga aattaactat 8640
ctgtacttat aaggtggttc ccctctctca gcgaagtggt gttcttgaat ggtgcacagg 8700
aactgtcccc attggtgaat ttcttgttaa caatgaagat ggtgctcata aaagatacag 8760
gccaaatgat ttcagtgcct ttcagtgcca aaagaaaatg atggaggtgc aaaaaaagtc 8820
ttttgaagag aaatatgaag tcttcatgga tgtttgccaa aattttcaac cagttttccg 8880
ttacttctgc atggaaaaat tcttggatcc agctatttgg tttgagaagc gattggctta 8940
tacgcgcagt gtagctactt cttctattgt tggttacata cttggacttg gtgatagaca 9000
tgtacagaat atcttgataa atgagcagtc agcagaactt gtacatatag atctaggtgt 9060
tgcttttgaa cagggcaaaa tccttcctac tcctgagaca gttcctttta gactcaccag 9120
agatattgtg gatggcatgg gcattacggg tgttgaaggt gtcttcagaa gatgctgtga 9180
gaaaaccatg gaagtgatga gaaactctca ggaaactctg ttaaccattg tagaggtcct 9240
tctatatgat ccactctttg actggaccat gaatcctttg aaagctttgt atttacagca 9300
gaggccggaa gatgaaactg agcttcaccc tactctgaat gcagatgacc aagaatgcaa 9360
acgaaatctc agtgatattg accagagttt caacaaagta gctgaacgtg tcttaatgag 9420
actacaagag aaactgaaag gagtggaaga aggcactgtg ctcagtgttg gtggacaagt 9480
gaatttgctc atacagcagg ccatagaccc caaaaatctc agccgacttt tcccaggatg 9540
gaaagcttgg gtgtgatctt cagtatatga attacccttt cattcagcct ttagaaatta 9600
tattttagcc tttattttta acctgccaac atactttaag tagggattaa tatttaagtg 9660
aactattgtg ggtttttttg aatgttggtt ttaatacttg atttaatcac cactcaaaaa 9720
tgttttgatg gtcttaagga acatctctgc tttcactctt tagaaataat ggtcattcgg 9780
gctgggcgca gcggctcacg cctgtaatcc cagcactttg ggaggccgag gtgagcggat 9840
cacaaggtca ggagttcgag accagcctgg ccaagagacc agcctggcca gtatggtgaa 9900
accctgtctc tactaaaaat acaaaaatta gccgagcatg gtggcgggca cctgtaatcc 9960
cagctactcg agaggctgag gcaggagaat ctcttgaacc tgggaggtga aggttgctgt 10020
gggccaaaat catgccattg cactccagcc tgggtgacaa gagcgaaact ccatctcaaa 10080
aaaaaaaaaa aaaaaacaga aacgtatttg gatttttcct agtaagatca ctcagtgtta 10140
ctaaataatg aagttgttat ggagaacaaa tttcaaagac acagttagtg tagttactat 10200
ttttttaagt gtgtattaaa acttctcatt ctattctctt tatcttttaa gcccttctgt 10260
actgtccatg tatgttatct ttctgtgata acttcataga ttgccttcta gttcatgaat 10320
tctcttgtca gatgtatata atctctttta ccctatccat tgggcttctt ctttcagaaa 10380
ttgtttttca tttctaatta tgcatcattt ttcagatctc tgtttcttga tgtcattttt 10440
aatgtttttt taatgttttt tatgtcacta attattttaa atgtctgtac ttgatagaca 10500
ctgtaatagt tctattaaat ttagttcctg ctgtttatat ctgttgattt ttgtatttga 10560
taggctgttc atccagtttt gtctttttga aaagtgagtt tattttcagc aaggctttat 10620
ctatgggaat cttgagtgtc tgtttatgtc atattcccag ggctgttgct gcacacaagc 10680
ccattcttat tttaatttct tggctttagg gtttccatac ctgaagtgta gcataaatac 10740
tgataggaga tttcccaggc caaggcaaac acacttcctc ctcatctcct tgtgctagtg 10800
ggcagaatat ttgattgatg cctttttcac tgagagtata agcttccatg tgtcccacct 10860
ttatggcagg ggtggaagga ggtacattta attcccactg cctgcctttg gcaagccctg 10920
ggttctttgc tccccatata gatgtctaag ctaaaagccg tgggttaatg agactggcaa 10980
attgttccag gacagctaca gcatcagctc acatattcac ctctctggtt tttcattccc 11040
ctcatttttt tctgagacag agtcttgctc tgtcacccag gctggagtgc agtggcatga 11100
tctcagctca ctgaaacctc tgcctcctgg gttcaagcaa ttctcctgcc tcagcctccc 11160
gagtagctgg gactacaggc gtgtgccaac acgcccggct aattttttgt atttttatta 11220
gagacggagt ttcaccgtgt tagccaggat ggtctcgatc gcttgacctc gtgatccacc 11280
ctcctcggcc tcccaaagtg ctgggattac aggtgtgagc caccgcgccc ggcctcattc 11340
ccctcatttt tgaccgtaag gatttcccct ttcttgtaag ttctgctatg tatttaaaag 11400
aatgttttct acattttatc cagcatttct ctgtgttctg ttggaaggga agggcttagg 11460
tatctagttt gatacatagg tagaagtgga acatttctct gtcccccagc tgtcatcata 11520
taagataaac atcagataaa aagccacctg aaagtaaaac tactgactcg tgtattagtg 11580
agtataatct cttctccatc cttaggaaaa tgttcatccc agctgcggag attaacaaat 11640
gggtgattga gctttctcct cgtatttgga ccttgaaggt tatataaatt tttttcttat 11700
gaagagttgg catttctttt tattgccaat ggcaggcact cattcatatt tgatctcctc 11760
accttcccct cccctaaaac caatctccag aactttttgg actataaatt tcttggtttg 11820
acttctggag aactgttcag aatattactt tgcatttcaa attacaaact taccttggtg 11880
tatctttttc ttacaagctg cctaaatgaa tatttggtat atattggtag ttttattact 11940
atagtaaatc aaggaaatgc agtaaactta aaatgtcttt aagaaagccc tgaaatcttc 12000
atgggtgaaa ttagaaatta tcaactagat aatagtatag ataaatgaat ttgtagctaa 12060
ttcttgctag ttgttgcatc cagagagctt tgaataacat cattaatcta ctctttagcc 12120
ttgcatggta tgctatgagg ctcctgttct gttcaagtat tctaatcaat ggctttgaaa 12180
agtttatcaa atttacatac agatcacaag cctaggagaa ataactaatt cacagatgac 12240
agaattaaga ttataaaaga tttttttttt gtaattttag tagagacagg gttgccattg 12300
tattccagcc ttggcgacag agcaagactc tgcctcaaaa aaaaaaaaaa aaaggttttg 12360
gcaagctgga actctttctg caaatgacta agatagaaaa ctgccaagga caaatgagga 12420
gtagttagat tttgaaaata ttaatcatag aatagttgtt gtatgctaag tcactgaccc 12480
atattatgta cagcatttct gatctttact ttgcaagatt agtgatacta tcccaataca 12540
ctgctggaga aatcagaatt tggagaaata agttgtccaa ggcaagaaga tagtaaatta 12600
taagtacaag tgtaatatgg acagtatcta acttgaaaag atttcaggcg aaaagaatct 12660
ggggtttgcc agtcagttgc tcaaaaggtc aatgaaaacc aaatagtgaa gctatcagag 12720
aagctaataa attatagact gcttgaacag ttgtgtccag attaagggag ataatagctt 12780
tcccacccta ctttgtgcag gtcatacctc cccaaagtgt ttacctaatc agtaggttca 12840
caaactcttg gtcattatag tatatgccta aaatgtatgc acttaggaat gctaaaaatt 12900
taaatatggt ctaaagcaaa taaaagcaaa gaggaaaaac tttggacagc gtaaagacta 12960
gaatagtctt ttaaaaagaa agccagtata ttggtttgaa atatagagat gtgtcccaat 13020
ttcaagtatt ttaattgcac cttaatgaaa ttatctattt tctatagatt ttagtactat 13080
tgaatgtatt actttactgt tacctgaatt tattataaag tgtttttgaa taaataattc 13140
taaaagc 13147
<210>6
<211>2644
<212>PRT
<213>Homo sapiens
<400>6
Met Gly Glu His Gly Leu Glu Leu Ala Ser Met Ile Pro Ala Leu Arg
1 5 10 15
Glu Leu Gly Ser Ala Thr Pro Glu Glu Tyr Asn Thr Val Val Gln Lys
20 25 30
Pro Arg Gln Ile Leu Cys Gln Phe Ile Asp Arg Ile Leu Thr Asp Val
35 40 45
Asn Val Val Ala Val Glu Leu Val Lys Lys Thr Asp Ser Gln Pro Thr
50 55 60
Ser Val Met Leu Leu Asp Phe Ile Gln His Ile Met Lys Ser Ser Pro
65 70 75 80
Leu Met Phe Val Asn Val Ser Gly Ser His Glu Arg Lys Gly Ser Cys
85 90 95
Ile Glu Phe Ser Asn Trp Ile Ile Thr Arg Leu Leu Arg Ile Ala Ala
100 105 110
Thr Pro Ser Cys His Leu Leu His Lys Lys Ile Cys Glu Val Ile Cys
115 120 125
Ser Leu Leu Phe Leu Phe Lys Ser Lys Ser Pro Ala Ile Phe Gly Val
130 135 140
Leu Thr Lys Glu Leu Leu Gln Leu Phe Glu Asp Leu Val Tyr Leu His
145 150 155 160
Arg Arg Asn Val Met Gly His Ala Val Glu Trp Pro Val Val Met Ser
165 170 175
Arg Phe Leu Ser Gln Leu Asp Glu His Met Gly Tyr Leu Gln Ser Ala
180 185 190
Pro Leu Gln Leu Met Ser Met Gln Asn Leu Glu Phe Ile Glu Val Thr
195 200 205
Leu Leu Met Val Leu Thr Arg Ile Ile Ala Ile Val Phe Phe Arg Arg
210 215 220
Gln Glu Leu Leu Leu Trp Gln Ile Gly Cys Val Leu Leu Glu Tyr Gly
225 230 235 240
Ser Pro Lys Ile Lys Ser Leu Ala Ile Ser Phe Leu Thr Glu Leu Phe
245 250 255
Gln Leu Gly Gly Leu Pro Ala Gln Pro Ala Ser Thr Phe Phe Ser Ser
260 265 270
Phe Leu Glu Leu Leu Lys His Leu Val Glu Met Asp Thr Asp Gln Leu
275 280 285
Lys Leu Tyr Glu Glu Pro Leu Ser Lys Leu Ile Lys Thr Leu Phe Pro
290 295 300
Phe Glu Ala Glu Ala Tyr Arg Asn Ile Glu Pro Val Tyr Leu Asn Met
305 310 315 320
Leu Leu Glu Lys Leu Cys Val Met Phe Glu Asp Gly Val Leu Met Arg
325 330 335
Leu Lys Ser Asp Leu Leu Lys Ala Ala Leu Cys His Leu Leu Gln Tyr
340 345 350
Phe Leu Lys Phe Val Pro Ala Gly Tyr Glu Ser Ala Leu Gln Val Arg
355 360 365
Lys Val Tyr Val Arg Asn Ile Cys Lys Ala Leu Leu Asp Val Leu Gly
370 375 380
Ile Glu Val Asp Ala Glu Tyr Leu Leu Gly Pro Leu Tyr Ala Ala Leu
385 390 395 400
Lys Met Glu Ser Met Glu Ile Ile Glu Glu Ile Gln Cys Gln Thr Gln
405 410 415
Gln Glu Asn Leu Ser Ser Asn Ser Asp Gly Ile Ser Pro Lys Arg Arg
420 425 430
Arg Leu Ser Ser Ser Leu Asn Pro Ser Lys Arg Ala Pro Lys Gln Thr
435 440 445
Glu Glu Ile Lys His Val Asp Met Asn Gln Lys Ser Ile Leu Trp Ser
450 455 460
Ala Leu Lys Gln Lys Ala Glu Ser Leu Gln Ile Ser Leu Glu Tyr Ser
465 470 475 480
Gly Leu Lys Asn Pro Val Ile Glu Met Leu Glu Gly Ile Ala Val Val
485 490 495
Leu Gln Leu Thr Ala Leu Cys Thr Val His Cys Ser His Gln Asn Met
500 505 510
Asn Cys Arg Thr Phe Lys Asp Cys Gln His Lys Ser Lys Lys Lys Pro
515 520 525
Ser Val Val Ile Thr Trp Met Ser Leu Asp Phe Tyr Thr Lys Val Leu
530 535 540
Lys Ser Cys Arg Ser Leu Leu Glu Ser Val Gln Lys Leu Asp Leu Glu
545 550 555 560
Ala Thr Ile Asp Lys Val Val Lys Ile Tyr Asp Ala Leu Ile Tyr Met
565 570 575
Gln Val Asn Ser Ser Phe Glu Asp His Ile Leu Glu Asp Leu Cys Gly
580 585 590
Met Leu Ser Leu Pro Trp Ile Tyr Ser His Ser Asp Asp Gly Cys Leu
595 600 605
Lys Leu Thr Thr Phe Ala Ala Asn Leu Leu Thr Leu Ser Cys Arg Ile
610 615 620
Ser Asp Ser Tyr Ser Pro Gln Ala Gln Ser Arg Cys Val Phe Leu Leu
625 630 635 640
Thr Leu Phe Pro Arg Arg Ile Phe Leu Glu Trp Arg Thr Ala Val Tyr
645 650 655
Asn Trp Ala Leu Gln Ser Ser His Glu Val Ile Arg Ala Ser Cys Val
660 665 670
Ser Gly Phe Phe Ile Leu Leu Gln Gln Gln Asn Ser Cys Asn Arg Val
675 680 685
Pro Lys Ile Leu Ile Asp Lys Val Lys Asp Asp Ser Asp Ile Val Lys
690 695 700
Lys Glu Phe Ala Ser Ile Leu Gly Gln Leu Val Cys Thr Leu His Gly
705 710 715 720
Met Phe Tyr Leu Thr Ser Ser Leu Thr Glu Pro Phe Ser Glu His Gly
725 730 735
His Val Asp Leu Phe Cys Arg Asn Leu Lys Ala Thr Ser Gln His Glu
740 745 750
Cys Ser Ser Ser Gln Leu Lys Ala Ser Val Cys Lys Pro Phe Leu Phe
755 760 765
Leu Leu Lys Lys Lys Ile Pro Ser Pro Val Lys Leu Ala Phe Ile Asp
770 775 780
Asn Leu His His Leu Cys Lys His Leu Asp Phe Arg Glu Asp Glu Thr
785 790 795 800
Asp Val Lys Ala Val Leu Gly Thr Leu Leu Asn Leu Met Glu Asp Pro
805 810 815
Asp Lys Asp Val Arg Val Ala Phe Ser Gly Asn Ile Lys His Ile Leu
820 825 830
Glu Ser Leu Asp Ser Glu Asp Gly Phe Ile Lys Glu Leu Phe Val Leu
835 840 845
Arg Met Lys Glu Ala Tyr Thr His Ala Gln Ile Ser Arg Asn Asn Glu
850 855 860
Leu Lys Asp Thr Leu Ile Leu Thr Thr Gly Asp Ile Gly Arg Ala Ala
865 870 875 880
Lys Gly Asp Leu Val Pro Phe Ala Leu Leu His Leu Leu His Cys Leu
885 890 895
Leu Ser Lys Ser Ala Ser Val Ser Gly Ala Ala Tyr Thr Glu Ile Arg
900 905 910
Ala Leu Val Ala Ala Lys Ser Val Lys Leu Gln Ser Phe Phe Ser Gln
915 920 925
Tyr Lys Lys Pro Ile Cys Gln Phe Leu Val Glu Ser Leu His Ser Ser
930 935 940
Gln Met Thr Ala Leu Pro Asn Thr Pro Cys Gln Asn Ala Asp Val Arg
945 950 955 960
Lys Gln Asp Val Ala His Gln Arg Glu Met Ala Leu Asn Thr Leu Ser
965 970 975
Glu Ile Ala Asn Val Phe Asp Phe Pro Asp Leu Asn Arg Phe Leu Thr
980 985 990
Arg Thr Leu Gln Val Leu Leu Pro Asp Leu Ala Ala Lys Ala Ser Pro
995 1000 1005
Ala Ala Ser Ala Leu Ile Arg Thr Leu Gly Lys Gln Leu Asn Val
1010 1015 1020
Asn Arg Arg Glu Ile Leu Ile Asn Asn Phe Lys Tyr Ile Phe Ser
1025 1030 1035
His Leu Val Cys Ser Cys Ser Lys Asp Glu Leu Glu Arg Ala Leu
1040 1045 1050
His Tyr Leu Lys Asn Glu Thr Glu Ile Glu Leu Gly Ser Leu Leu
1055 1060 1065
Arg Gln Asp Phe Gln Gly Leu His Asn Glu Leu Leu Leu Arg Ile
1070 1075 1080
Gly Glu His Tyr Gln Gln Val Phe Asn Gly Leu Ser Ile Leu Ala
1085 1090 1095
Ser Phe Ala Ser Ser Asp Asp Pro Tyr Gln Gly Pro Arg Asp Ile
1100 1105 1110
Ile Ser Pro Glu Leu Met Ala Asp Tyr Leu Gln Pro Lys Leu Leu
1115 1120 1125
Gly Ile Leu Ala Phe Phe Asn Met Gln Leu Leu Ser Ser Ser Val
1130 1135 1140
Gly Ile Glu Asp Lys Lys Met Ala Leu Asn Ser Leu Met Ser Leu
1145 1150 1155
Met Lys Leu Met Gly Pro Lys His Val Ser Ser Val Arg Val Lys
1160 1165 1170
Met Met Thr Thr Leu Arg Thr Gly Leu Arg Phe Lys Asp Asp Phe
1175 1180 1185
Pro Glu Leu Cys Cys Arg Ala Trp Asp Cys Phe Val Arg Cys Leu
1190 1195 1200
Asp His Ala Cys Leu Gly Ser Leu Leu Ser His Val Ile Val Ala
1205 1210 1215
Leu Leu Pro Leu Ile His Ile Gln Pro Lys Glu Thr Ala Ala Ile
1220 1225 1230
Phe His Tyr Leu Ile Ile Glu Asn Arg Asp Ala Val Gln Asp Phe
1235 1240 1245
Leu His Glu Ile Tyr Phe Leu Pro Asp His Pro Glu Leu Lys Lys
1250 1255 1260
Ile Lys Ala Val Leu Gln Glu Tyr Arg Lys Glu Thr Ser Glu Ser
1265 1270 1275
Thr Asp Leu Gln Thr Thr Leu Gln Leu Ser Met Lys Ala Ile Gln
1280 1285 1290
His Glu Asn Val Asp Val Arg Ile His Ala Leu Thr Ser Leu Lys
1295 1300 1305
Glu Thr Leu Tyr Lys Asn Gln Glu Lys Leu Ile Lys Tyr Ala Thr
1310 1315 1320
Asp Ser Glu Thr Val Glu Pro Ile Ile Ser Gln Leu Val Thr Val
1325 1330 1335
Leu Leu Lys Gly Cys Gln Asp Ala Asn Ser Gln Ala Arg Leu Leu
1340 1345 1350
Cys Gly Glu Cys Leu Gly Glu Leu Gly Ala Ile Asp Pro Gly Arg
1355 1360 1365
Leu Asp Phe Ser Thr Thr Glu Thr Gln Gly Lys Asp Phe Thr Phe
1370 1375 1380
Val Thr Gly Val Glu Asp Ser Ser Phe Ala Tyr Gly Leu Leu Met
1385 1390 1395
Glu Leu Thr Arg Ala Tyr Leu Ala Tyr Ala Asp Asn Ser Arg Ala
1400 1405 1410
Gln Asp Ser Ala Ala Tyr Ala Ile Gln Glu Leu Leu Ser Ile Tyr
1415 1420 1425
Asp Cys Arg Glu Met Glu Thr Asn Gly Pro Gly His Gln Leu Trp
1430 1435 1440
Arg Arg Phe Pro Glu His Val Arg Glu Ile Leu Glu Pro His Leu
1445 1450 1455
Asn Thr Arg Tyr Lys Ser Ser Gln Lys Ser Thr Asp Trp Ser Gly
1460 1465 1470
Val Lys Lys Pro Ile Tyr Leu Ser Lys Leu Gly Ser Asn Phe Ala
1475 1480 1485
Glu Trp Ser Ala Ser Trp Ala Gly Tyr Leu Ile Thr Lys Val Arg
1490 1495 1500
His Asp Leu Ala Ser Lys Ile Phe Thr Cys Cys Ser Ile Met Met
1505 1510 1515
Lys His Asp Phe Lys Val Thr Ile Tyr Leu Leu Pro His Ile Leu
1520 1525 1530
Val Tyr Val Leu Leu Gly Cys Asn Gln Glu Asp Gln Gln Glu Val
1535 1540 1545
Tyr Ala Glu Ile Met Ala Val Leu Lys His Asp Asp Gln His Thr
1550 1555 1560
Ile Asn Thr Gln Asp Ile Ala Ser Asp Leu Cys Gln Leu Ser Thr
1565 1570 1575
Gln Thr Val Phe Ser Met Leu Asp His Leu Thr Gln Trp Ala Arg
1580 1585 1590
His Lys Phe Gln Ala Leu Lys Ala Glu Lys Cys Pro His Ser Lys
1595 1600 1605
Ser Asn Arg Asn Lys Val Asp Ser Met Val Ser Thr Val Asp Tyr
1610 1615 1620
Glu Asp Tyr Gln Ser Val Thr Arg Phe Leu Asp Leu Ile Pro Gln
1625 1630 1635
Asp Thr Leu Ala Val Ala Ser Phe Arg Ser Lys Ala Tyr Thr Arg
1640 1645 1650
Ala Val Met His Phe Glu Ser Phe Ile Thr Glu Lys Lys Gln Asn
1655 1660 1665
Ile Gln Glu His Leu Gly Phe Leu Gln Lys Leu Tyr Ala Ala Met
1670 1675 1680
His Glu Pro Asp Gly Val Ala Gly Val Ser Ala Ile Arg Lys Ala
1685 1690 1695
Glu Pro Ser Leu Lys Glu Gln Ile Leu Glu His Glu Ser Leu Gly
1700 1705 1710
Leu Leu Arg Asp Ala Thr Ala Cys Tyr Asp Arg Ala Ile Gln Leu
1715 1720 1725
Glu Pro Asp Gln Ile Ile His Tyr His Gly Val Val Lys Ser Met
1730 1735 1740
Leu Gly Leu Gly Gln Leu Ser Thr Val Ile Thr Gln Val Asn Gly
1745 1750 1755
Val His Ala Asn Arg Ser Glu Trp Thr Asp Glu Leu Asn Thr Tyr
1760 1765 1770
Arg Val Glu Ala Ala Trp Lys Leu Ser Gln Trp Asp Leu Val Glu
1775 1780 1785
Asn Tyr Leu Ala Ala Asp Gly Lys Ser Thr Thr Trp Ser Val Arg
1790 1795 1800
Leu Gly Gln Leu Leu Leu Ser Ala Lys Lys Arg Asp Ile Thr Ala
1805 1810 1815
Phe Tyr Asp Ser Leu Lys Leu Val Arg Ala Glu Gln Ile Val Pro
1820 1825 1830
Leu Ser Ala Ala Ser Phe Glu Arg Gly Ser Tyr Gln Arg Gly Tyr
1835 1840 1845
Glu Tyr Ile Val Arg Leu His Met Leu Cys Glu Leu Glu His Ser
1850 1855 1860
Ile Lys Pro Leu Phe Gln His Ser Pro Gly Asp Ser Ser Gln Glu
1865 1870 1875
Asp Ser Leu Asn Trp Val Ala Arg Leu Glu Met Thr Gln Asn Ser
1880 1885 1890
Tyr Arg Ala Lys Glu Pro Ile Leu Ala Leu Arg Arg Ala Leu Leu
1895 1900 1905
Ser Leu Asn Lys Arg Pro Asp Tyr Asn Glu Met Val Gly Glu Cys
1910 1915 1920
Trp Leu Gln Ser Ala Arg Val Ala Arg Lys Ala Gly His His Gln
1925 1930 1935
Thr Ala Tyr Asn Ala Leu Leu Asn Ala Gly Glu Ser Arg Leu Ala
1940 1945 1950
Glu Leu Tyr Val Glu Arg Ala Lys Trp Leu Trp Ser Lys Gly Asp
1955 1960 1965
Val His Gln Ala Leu Ile Val Leu Gln Lys Gly Val Glu Leu Cys
1970 1975 1980
Phe Pro Glu Asn Glu Thr Pro Pro Glu Gly Lys Asn Met Leu Ile
1985 1990 1995
His Gly Arg Ala Met Leu Leu Val Gly Arg Phe Met Glu Glu Thr
2000 2005 2010
Ala Asn Phe Glu Ser Asn Ala Ile Met Lys Lys Tyr Lys Asp Val
2015 2020 2025
Thr Ala Cys Leu Pro Glu Trp Glu Asp Gly His Phe Tyr Leu Ala
2030 2035 2040
Lys Tyr Tyr Asp Lys Leu Met Pro Met Val Thr Asp Asn Lys Met
2045 2050 2055
Glu Lys Gln Gly Asp Leu Ile Arg Tyr Ile Val Leu His Phe Gly
2060 2065 2070
Arg Ser Leu Gln Tyr Gly Asn Gln Phe Ile Tyr Gln Ser Met Pro
2075 2080 2085
Arg Met Leu Thr Leu Trp Leu Asp Tyr Gly Thr Lys Ala Tyr Glu
2090 2095 2100
Trp Glu Lys Ala Gly Arg Ser Asp Arg Val Gln Met Arg Asn Asp
2105 2110 2115
Leu Gly Lys Ile Asn Lys Val Ile Thr Glu His Thr Asn Tyr Leu
2120 2125 2130
Ala Pro Tyr Gln Phe Leu Thr Ala Phe Ser Gln Leu Ile Ser Arg
2135 2140 2145
Ile Cys His Ser His Asp Glu Val Phe Val Val Leu Met Glu Ile
2150 2155 2160
Ile Ala Lys Val Phe Leu Ala Tyr Pro Gln Gln Ala Met Trp Met
2165 2170 2175
Met Thr Ala Val Ser Lys Ser Ser Tyr Pro Met Arg Val Asn Arg
2180 2185 2190
Cys Lys Glu Ile Leu Asn Lys Ala Ile His Met Lys Lys Ser Leu
2195 2200 2205
Glu Lys Phe Val Gly Asp Ala Thr Arg Leu Thr Asp Lys Leu Leu
2210 2215 2220
Glu Leu Cys Asn Lys Pro Val Asp Gly Ser Ser Ser Thr Leu Ser
2225 2230 2235
Met Ser Thr His Phe Lys Met Leu Lys Lys Leu Val Glu Glu Ala
2240 2245 2250
Thr Phe Ser Glu Ile Leu Ile Pro Leu Gln Ser Val Met Ile Pro
2255 2260 2265
Thr Leu Pro Ser Ile Leu Gly Thr His Ala Asn His Ala Ser His
2270 2275 2280
Glu Pro Phe Pro Gly His Trp Ala Tyr Ile Ala Gly Phe Asp Asp
2285 2290 2295
Met Val Glu Ile Leu Ala Ser Leu Gln Lys Pro Lys Lys Ile Ser
2300 2305 2310
Leu Lys Gly Ser Asp Gly Lys Phe Tyr Ile Met Met Cys Lys Pro
2315 2320 2325
Lys Asp Asp Leu Arg Lys Asp Cys Arg Leu Met Glu Phe Asn Ser
2330 2335 2340
Leu Ile Asn Lys Cys Leu Arg Lys Asp Ala Glu Ser Arg Arg Arg
2345 2350 2355
Glu Leu His Ile Arg Thr Tyr Ala Val Ile Pro Leu Asn Asp Glu
2360 2365 2370
Cys Gly Ile Ile Glu Trp Val Asn Asn Thr Ala Gly Leu Arg Pro
2375 2380 2385
Ile Leu Thr Lys Leu Tyr Lys Glu Lys Gly Val Tyr Met Thr Gly
2390 2395 2400
Lys Glu Leu Arg Gln Cys Met Leu Pro Lys Ser Ala Ala Leu Ser
2405 2410 2415
Glu Lys Leu Lys Val Phe Arg Glu Phe Leu Leu Pro Arg His Pro
2420 2425 2430
Pro Ile Phe His Glu Trp Phe Leu Arg Thr Phe Pro Asp Pro Thr
2435 2440 2445
Ser Trp Tyr Ser Ser Arg Ser Ala Tyr Cys Arg Ser Thr Ala Val
2450 2455 2460
Met Ser Met Val Gly Tyr Ile Leu Gly Leu Gly Asp Arg His Gly
2465 2470 2475
Glu Asn Ile Leu Phe Asp Ser Leu Thr Gly Glu Cys Val His Val
2480 2485 2490
Asp Phe Asn Cys Leu Phe Asn Lys Gly Glu Thr Phe Glu Val Pro
2495 2500 2505
Glu Ile Val Pro Phe Arg Leu Thr His Asn Met Val Asn Gly Met
2510 2515 2520
Gly Pro Met Gly Thr Glu Gly Leu Phe Arg Arg Ala Cys Glu Val
2525 2530 2535
Thr Met Arg Leu Met Arg Asp Gln Arg Glu Pro Leu Met Ser Val
2540 2545 2550
Leu Lys Thr Phe Leu His Asp Pro Leu Val Glu Trp Ser Lys Pro
2555 2560 2565
Val Lys Gly His Ser Lys Ala Pro Leu Asn Glu Thr Gly Glu Val
2570 2575 2580
Val Asn Glu Lys Ala Lys Thr His Val Leu Asp Ile Glu Gln Arg
2585 2590 2595
Leu Gln Gly Val Ile Lys Thr Arg Asn Arg Val Thr Gly Leu Pro
2600 2605 2610
Leu Ser Ile Glu Gly His Val His Tyr Leu Ile Gln Glu Ala Thr
2615 2620 2625
Asp Glu Asn Leu Leu Cys Gln Met Tyr Leu Gly Trp Thr Pro Tyr
2630 2635 2640
Met
<210>7
<211>3056
<212>PRT
<213>Homo sapiens
<400>7
Met Ser Leu Val Leu Asn Asp Leu Leu Ile Cys Cys Arg Gln Leu Glu
1 5 10 15
His Asp Arg Ala Thr Glu Arg Lys Lys Glu Val Glu Lys Phe Lys Arg
20 25 30
Leu Ile Arg Asp Pro Glu Thr Ile Lys His Leu Asp Arg His Ser Asp
35 40 45
Ser Lys Gln Gly Lys Tyr Leu Asn Trp Asp Ala Val Phe Arg Phe Leu
50 55 60
Gln Lys Tyr Ile Gln Lys Glu Thr Glu Cys Leu Arg Ile Ala Lys Pro
65 70 75 80
Asn Val Ser Ala Ser Thr Gln Ala Ser Arg Gln Lys Lys Met Gln Glu
85 90 95
Ile Ser Ser Leu Val Lys Tyr Phe Ile Lys Cys Ala Asn Arg Arg Ala
100 105 110
Pro Arg Leu Lys Cys Gln Glu Leu Leu Asn Tyr Ile Met Asp Thr Val
115 120 125
Lys Asp Ser Ser Asn Gly Ala Ile Tyr Gly Ala Asp Cys Ser Asn Ile
130 135 140
Leu Leu Lys Asp Ile Leu Ser Val Arg Lys Tyr Trp Cys Glu Ile Ser
145 150 155 160
Gln Gln Gln Trp Leu Glu Leu Phe Ser Val Tyr Phe Arg Leu Tyr Leu
165 170 175
Lys Pro Ser Gln Asp Val His Arg Val Leu Val Ala Arg Ile Ile His
180 185 190
Ala Val Thr Lys Gly Cys Cys Ser Gln Thr Asp Gly Leu Asn Ser Lys
195 200 205
Phe Leu Asp Phe Phe Ser Lys Ala Ile Gln Cys Ala Arg Gln Glu Lys
210 215 220
Ser Ser Ser Gly Leu Asn His Ile Leu Ala Ala Leu Thr Ile Phe Leu
225 230 235 240
Lys Thr Leu Ala Val Asn Phe Arg Ile Arg Val Cys Glu Leu Gly Asp
245 250 255
Glu Ile Leu Pro Thr Leu Leu Tyr Ile Trp Thr Gln His Arg Leu Asn
260 265 270
Asp Ser Leu Lys Glu Val Ile Ile Glu Leu Phe Gln Leu Gln Ile Tyr
275 280 285
Ile His His Pro Lys Gly Ala Lys Thr Gln Glu Lys Gly Ala Tyr Glu
290 295 300
Ser Thr Lys Trp Arg Ser Ile Leu Tyr Asn Leu Tyr Asp Leu Leu Val
305 310 315 320
Asn Glu Ile Ser His Ile Gly Ser Arg Gly Lys Tyr Ser Ser Gly Phe
325 330 335
Arg Asn Ile Ala Val Lys Glu Asn Leu Ile Glu Leu Met Ala Asp Ile
340 345 350
Cys His Gln Val Phe Asn Glu Asp Thr Arg Ser Leu Glu Ile Ser Gln
355 360 365
Ser Tyr Thr Thr Thr Gln Arg Glu Ser Ser Asp Tyr Ser Val Pro Cys
370 375 380
Lys Arg Lys Lys Ile Glu Leu Gly Trp Glu Val Ile Lys Asp His Leu
385 390 395 400
Gln Lys Ser Gln Asn Asp Phe Asp Leu Val Pro Trp Leu Gln Ile Ala
405 410 415
Thr Gln Leu Ile Ser Lys Tyr Pro Ala Ser Leu Pro Asn Cys Glu Leu
420 425 430
Ser Pro Leu Leu Met Ile Leu Ser Gln Leu Leu Pro Gln Gln Arg His
435 440 445
Gly Glu Arg Thr Pro Tyr Val Leu Arg Cys Leu Thr Glu Val Ala Leu
450 455 460
Cys Gln Asp Lys Arg Ser Asn Leu Glu Ser Ser Gln Lys Ser Asp Leu
465 470 475 480
Leu Lys Leu Trp Asn Lys Ile Trp Cys Ile Thr Phe Arg Gly Ile Ser
485 490 495
Ser Glu Gln Ile Gln Ala Glu Asn Phe Gly Leu Leu Gly Ala Ile Ile
500 505 510
Gln Gly Ser Leu Val Glu Val Asp Arg Glu Phe Trp Lys Leu Phe Thr
515 520 525
Gly Ser Ala Cys Arg Pro Ser Cys Pro Ala Val Cys Cys Leu Thr Leu
530 535 540
Ala Leu Thr Thr Ser Ile Val Pro Gly Thr Val Lys Met Gly Ile Glu
545 550 555 560
Gln Asn Met Cys Glu Val Asn Arg Ser Phe Ser Leu Lys Glu Ser Ile
565 570 575
Met Lys Trp Leu Leu Phe Tyr Gln Leu Glu Gly Asp Leu Glu Asn Ser
580 585 590
Thr Glu Val Pro Pro Ile Leu His Ser Asn Phe Pro His Leu Val Leu
595 600 605
Glu Lys Ile Leu Val Ser Leu Thr Met Lys Asn Cys Lys Ala Ala Met
610 615 620
Asn Phe Phe Gln Ser Val Pro Glu Cys Glu His His Gln Lys Asp Lys
625 630 635 640
Glu Glu Leu Ser Phe Ser Glu Val Glu Glu Leu Phe Leu Gln Thr Thr
645 650 655
Phe Asp Lys Met Asp Phe Leu Thr Ile Val Arg Glu Cys Gly Ile Glu
660 665 670
Lys His Gln Ser Ser Ile Gly Phe Ser Val His Gln Asn Leu Lys Glu
675 680 685
Ser Leu Asp Arg Cys Leu Leu Gly Leu Ser Glu Gln Leu Leu Asn Asn
690 695 700
Tyr Ser Ser Glu Ile Thr Asn Ser Glu Thr Leu Val Arg Cys Ser Arg
705 710 715 720
Leu Leu Val Gly Val Leu Gly Cys Tyr Cys Tyr Met Gly Val Ile Ala
725 730 735
Glu Glu Glu Ala Tyr Lys Ser Glu Leu Phe Gln Lys Ala Lys Ser Leu
740 745 750
Met Gln Cys Ala Gly Glu Ser Ile Thr Leu Phe Lys Asn Lys Thr Asn
755 760 765
Glu Glu Phe Arg Ile Gly Ser Leu Arg Asn Met Met Gln Leu Cys Thr
770 775 780
Arg Cys Leu Ser Asn Cys Thr Lys Lys Ser Pro Asn Lys Ile Ala Ser
785 790 795 800
Gly Phe Phe Leu Arg Leu Leu Thr Ser Lys Leu Met Asn Asp Ile Ala
805 810 815
Asp Ile Cys Lys Ser Leu Ala Ser Phe Ile Lys Lys Pro Phe Asp Arg
820 825 830
Gly Glu Val Glu Ser Met Glu Asp Asp Thr Asn Gly Asn Leu Met Glu
835 840 845
Val Glu Asp Gln Ser Ser Met Asn Leu Phe Asn Asp Tyr Pro Asp Ser
850 855 860
Ser Val Ser Asp Ala Asn Glu Pro Gly Glu Ser Gln Ser Thr Ile Gly
865 870 875 880
Ala Ile Asn Pro Leu Ala Glu Glu Tyr Leu Ser Lys Gln Asp Leu Leu
885 890 895
Phe Leu Asp Met Leu Lys Phe Leu Cys Leu Cys Val Thr Thr Ala Gln
900 905 910
Thr Asn Thr Val Ser Phe Arg Ala Ala Asp Ile Arg Arg Lys Leu Leu
915 920 925
Met Leu Ile Asp Ser Ser Thr Leu Glu Pro Thr Lys Ser Leu His Leu
930 935 940
His Met Tyr Leu Met Leu Leu Lys Glu Leu Pro Gly Glu Glu Tyr Pro
945 950 955 960
Leu Pro Met Glu Asp Val Leu Glu Leu Leu Lys Pro Leu Ser Asn Val
965 970 975
Cys Ser Leu Tyr Arg Arg Asp Gln Asp Val Cys Lys Thr Ile Leu Asn
980 985 990
His Val Leu His Val Val Lys Asn Leu Gly Gln Ser Asn Met Asp Ser
995 1000 1005
Glu Asn Thr Arg Asp Ala Gln Gly Gln Phe Leu Thr Val Ile Gly
1010 1015 1020
Ala Phe Trp His Leu Thr Lys Glu Arg Lys Tyr Ile Phe Ser Val
1025 1030 1035
Arg Met Ala Leu Val Asn Cys Leu Lys Thr Leu Leu Glu Ala Asp
1040 1045 1050
Pro Tyr Ser Lys Trp Ala Ile Leu Asn Val Met Gly Lys Asp Phe
1055 1060 1065
Pro Val Asn Glu Val Phe Thr Gln Phe Leu Ala Asp Asn His His
1070 1075 1080
Gln Val Arg Met Leu Ala Ala Glu Ser Ile Asn Arg Leu Phe Gln
1085 1090 1095
Asp Thr Lys Gly Asp Ser Ser Arg Leu Leu Lys Ala Leu Pro Leu
1100 1105 1110
Lys Leu Gln Gln Thr Ala Phe Glu Asn Ala Tyr Leu Lys Ala Gln
1115 1120 1125
Glu Gly Met Arg Glu Met Ser His Ser Ala Glu Asn Pro Glu Thr
1130 1135 1140
Leu Asp Glu Ile Tyr Asn Arg Lys Ser Val Leu Leu Thr Leu Ile
1145 1150 1155
Ala Val Val Leu Ser Cys Ser Pro Ile Cys Glu Lys Gln Ala Leu
1160 1165 1170
Phe Ala Leu Cys Lys Ser Val Lys Glu Asn Gly Leu Glu Pro His
1175 1180 1185
Leu Val Lys Lys Val Leu Glu Lys Val Ser Glu Thr Phe Gly Tyr
1190 1195 1200
Arg Arg Leu Glu Asp Phe Met Ala Ser His Leu Asp Tyr Leu Val
1205 1210 1215
Leu Glu Trp Leu Asn Leu Gln Asp Thr Glu Tyr Asn Leu Ser Ser
1220 1225 1230
Phe Pro Phe Ile Leu Leu Asn Tyr Thr Asn Ile Glu Asp Phe Tyr
1235 1240 1245
Arg Ser Cys Tyr Lys Val Leu Ile Pro His Leu Val Ile Arg Ser
1250 1255 1260
His Phe Asp Glu Val Lys Ser Ile Ala Asn Gln Ile Gln Glu Asp
1265 1270 1275
Trp Lys Ser Leu Leu Thr Asp Cys Phe Pro Lys Ile Leu Val Asn
1280 1285 1290
Ile Leu Pro Tyr Phe Ala Tyr Glu Gly Thr Arg Asp Ser Gly Met
1295 1300 1305
Ala Gln Gln Arg Glu Thr Ala Thr Lys Val Tyr Asp Met Leu Lys
1310 1315 1320
Ser Glu Asn Leu Leu Gly Lys Gln Ile Asp His Leu Phe Ile Ser
1325 1330 1335
Asn Leu Pro Glu Ile Val Val Glu Leu Leu Met Thr Leu His Glu
1340 1345 1350
Pro Ala Asn Ser Ser Ala Ser Gln Ser Thr Asp Leu Cys Asp Phe
1355 1360 1365
Ser Gly Asp Leu Asp Pro Ala Pro Asn Pro Pro His Phe Pro Ser
1370 1375 1380
His Val Ile Lys Ala Thr Phe Ala Tyr Ile Ser Asn Cys His Lys
1385 1390 1395
Thr Lys Leu Lys Ser Ile Leu Glu Ile Leu Ser Lys Ser Pro Asp
1400 1405 1410
Ser Tyr Gln Lys Ile Leu Leu Ala Ile Cys Glu Gln Ala Ala Glu
1415 1420 1425
Thr Asn Asn Val Tyr Lys Lys His ArgIle Leu Lys Ile Tyr His
1430 1435 1440
Leu Phe Val Ser Leu Leu Leu Lys Asp Ile Lys Ser Gly Leu Gly
1445 1450 1455
Gly Ala Trp Ala Phe Val Leu Arg Asp Val Ile Tyr Thr Leu Ile
1460 1465 1470
His Tyr Ile Asn Gln Arg Pro Ser Cys Ile Met Asp Val Ser Leu
1475 1480 1485
Arg Ser Phe Ser Leu Cys Cys Asp Leu Leu Ser Gln Val Cys Gln
1490 1495 1500
Thr Ala Val Thr Tyr Cys Lys Asp Ala Leu Glu Asn His Leu His
1505 1510 1515
Val Ile Val Gly Thr Leu Ile Pro Leu Val Tyr Glu Gln Val Glu
1520 1525 1530
Val Gln Lys Gln Val Leu Asp Leu Leu Lys Tyr Leu Val Ile Asp
1535 1540 1545
Asn Lys Asp Asn Glu Asn Leu Tyr Ile Thr Ile Lys Leu Leu Asp
1550 1555 1560
Pro Phe Pro Asp His Val Val Phe Lys Asp Leu Arg Ile Thr Gln
1565 1570 1575
Gln Lys Ile Lys Tyr Ser Arg Gly Pro Phe Ser Leu Leu Glu Glu
1580 1585 1590
Ile Asn His Phe Leu Ser Val Ser Val Tyr Asp Ala Leu Pro Leu
1595 1600 1605
Thr Arg Leu Glu Gly Leu Lys Asp Leu Arg Arg Gln Leu Glu Leu
1610 1615 1620
His Lys Asp Gln Met Val Asp Ile Met Arg Ala Ser Gln Asp Asn
1625 1630 1635
Pro Gln Asp Gly Ile Met Val Lys Leu Val Val Asn Leu Leu Gln
1640 1645 1650
Leu Ser Lys Met Ala Ile Asn His Thr Gly Glu Lys Glu Val Leu
1655 1660 1665
Glu Ala Val Gly Ser Cys Leu Gly Glu Val Gly Pro Ile Asp Phe
1670 1675 1680
Ser Thr Ile Ala Ile Gln His Ser Lys Asp Ala Ser Tyr Thr Lys
1685 1690 1695
Ala Leu Lys Leu Phe Glu Asp Lys Glu Leu Gln Trp Thr Phe Ile
1700 1705 1710
Met Leu Thr Tyr Leu Asn Asn Thr Leu Val Glu Asp Cys Val Lys
1715 1720 1725
Val Arg Ser Ala Ala Val Thr Cys Leu Lys Asn Ile Leu Ala Thr
1730 1735 1740
Lys Thr Gly His Ser Phe Trp Glu Ile Tyr Lys Met Thr Thr Asp
1745 1750 1755
Pro Met Leu Ala Tyr Leu Gln Pro Phe Arg Thr Ser Arg Lys Lys
1760 1765 1770
Phe Leu Glu Val Pro Arg Phe Asp Lys Glu Asn Pro Phe Glu Gly
1775 1780 1785
Leu Asp Asp Ile Asn Leu Trp Ile Pro Leu Ser Glu Asn His Asp
1790 1795 1800
Ile Trp Ile Lys Thr Leu Thr Cys Ala Phe Leu Asp Ser Gly Gly
1805 1810 1815
Thr Lys Cys Glu Ile Leu Gln Leu Leu Lys Pro Met Cys Glu Val
1820 1825 1830
Lys Thr Asp Phe Cys Gln Thr Val Leu Pro Tyr Leu Ile His Asp
1835 1840 1845
Ile Leu Leu Gln Asp Thr Asn Glu Ser Trp Arg Asn Leu Leu Ser
1850 1855 1860
Thr His Val Gln Gly Phe Phe Thr Ser Cys Leu Arg His Phe Ser
1865 1870 1875
Gln Thr Ser Arg Ser Thr Thr Pro Ala Asn Leu Asp Ser Glu Ser
1880 1885 1890
Glu His Phe Phe Arg Cys Cys Leu Asp Lys Lys Ser Gln Arg Thr
1895 1900 1905
Met Leu Ala Val Val Asp Tyr Met Arg Arg Gln Lys Arg Pro Ser
1910 1915 1920
Ser Gly Thr Ile Phe Asn Asp Ala Phe Trp Leu Asp Leu Asn Tyr
1925 1930 1935
Leu Glu Val Ala Lys Val Ala Gln Ser Cys Ala Ala His Phe Thr
1940 1945 1950
Ala Leu Leu Tyr Ala Glu Ile Tyr Ala Asp Lys Lys Ser Met Asp
1955 1960 1965
Asp Gln Glu Lys Arg Ser Leu Ala Phe Glu Glu Gly Ser Gln Ser
1970 1975 1980
Thr Thr Ile Ser Ser Leu Ser Glu Lys Ser Lys Glu Glu Thr Gly
1985 1990 1995
Ile Ser Leu Gln Asp Leu Leu Leu Glu Ile Tyr Arg Ser Ile Gly
2000 2005 2010
Glu Pro Asp Ser Leu Tyr Gly Cys Gly Gly Gly Lys Met Leu Gln
2015 2020 2025
Pro Ile Thr Arg Leu Arg Thr Tyr Glu His Glu Ala Met Trp Gly
2030 2035 2040
Lys Ala Leu Val Thr Tyr Asp Leu Glu Thr Ala Ile Pro Ser Ser
2045 2050 2055
Thr Arg Gln Ala Gly Ile Ile Gln Ala Leu Gln Asn Leu Gly Leu
2060 2065 2070
Cys His Ile Leu Ser Val Tyr Leu Lys Gly Leu Asp Tyr Glu Asn
2075 2080 2085
Lys Asp Trp Cys Pro Glu Leu Glu Glu Leu His Tyr Gln Ala Ala
2090 2095 2100
Trp Arg Asn Met Gln Trp Asp His Cys Thr Ser Val Ser Lys Glu
2105 2110 2115
Val Glu Gly Thr Ser Tyr His Glu Ser Leu Tyr Asn Ala Leu Gln
2120 2125 2130
Ser Leu Arg Asp Arg Glu Phe Ser Thr Phe Tyr Glu Ser Leu Lys
2135 2140 2145
Tyr Ala Arg Val Lys Glu Val Glu Glu Met Cys Lys Arg Ser Leu
2150 2155 2160
Glu Ser Val Tyr Ser Leu Tyr Pro Thr Leu Ser Arg Leu Gln Ala
2165 2170 2175
Ile Gly Glu Leu Glu Ser Ile Gly Glu Leu Phe Ser Arg Ser Val
2180 2185 2190
Thr His Arg Gln Leu Ser Glu Val Tyr Ile Lys Trp Gln Lys His
2195 2200 2205
Ser Gln Leu Leu Lys Asp Ser Asp Phe Ser Phe Gln Glu Pro Ile
2210 2215 2220
Met Ala Leu Arg Thr Val Ile Leu Glu Ile Leu Met Glu Lys Glu
2225 2230 2235
Met Asp Asn Ser Gln Arg Glu Cys Ile Lys Asp Ile Leu Thr Lys
2240 2245 2250
His Leu Val Glu Leu Ser Ile Leu Ala Arg Thr Phe Lys Asn Thr
2255 2260 2265
Gln Leu Pro Glu Arg Ala Ile Phe Gln Ile Lys Gln Tyr Asn Ser
2270 2275 2280
Val Ser Cys Gly Val Ser Glu Trp Gln Leu Glu Glu Ala Gln Val
2285 2290 2295
Phe Trp Ala Lys Lys Glu Gln Ser Leu Ala Leu Ser Ile Leu Lys
2300 2305 2310
Gln Met Ile Lys Lys Leu Asp Ala Ser Cys Ala Ala Asn Asn Pro
2315 2320 2325
Ser Leu Lys Leu Thr Tyr Thr Glu Cys Leu Arg Val Cys Gly Asn
2330 2335 2340
Trp Leu Ala Glu Thr Cys Leu Glu Asn Pro Ala Val Ile Met Gln
2345 2350 2355
Thr Tyr Leu Glu Lys Ala Val Glu Val Ala Gly Asn Tyr Asp Gly
2360 2365 2370
Glu Ser Ser Asp Glu Leu Arg Asn Gly Lys Met Lys Ala Phe Leu
2375 2380 2385
Ser Leu Ala Arg Phe Ser Asp Thr Gln Tyr Gln Arg Ile Glu Asn
2390 2395 2400
Tyr Met Lys Ser Ser Glu Phe Glu Asn Lys Gln Ala Leu Leu Lys
2405 2410 2415
Arg Ala Lys Glu Glu Val Gly Leu Leu Arg Glu His Lys Ile Gln
2420 2425 2430
Thr Asn Arg Tyr Thr Val Lys Val Gln Arg Glu Leu Glu Leu Asp
2435 2440 2445
Glu Leu Ala Leu Arg Ala Leu Lys Glu Asp Arg Lys Arg Phe Leu
2450 2455 2460
Cys Lys Ala Val Glu Asn Tyr Ile Asn Cys Leu Leu Ser Gly Glu
2465 2470 2475
Glu His Asp Met Trp Val Phe Arg Leu Cys Ser Leu Trp Leu Glu
2480 2485 2490
Asn Ser Gly Val Ser Glu Val Asn Gly Met Met Lys Arg Asp Gly
2495 2500 2505
Met Lys Ile Pro Thr Tyr Lys Phe Leu Pro Leu Met Tyr Gln Leu
2510 2515 2520
Ala Ala Arg Met Gly Thr Lys Met Met Gly Gly Leu Gly Phe His
2525 2530 2535
Glu Val Leu Asn Asn Leu Ile Ser Arg Ile Ser Met Asp His Pro
2540 2545 2550
His His Thr Leu Phe Ile Ile Leu Ala Leu Ala Asn Ala Asn Arg
2555 2560 2565
Asp Glu Phe Leu Thr Lys Pro Glu Val Ala Arg Arg Ser Arg Ile
2570 2575 2580
Thr Lys Asn Val Pro Lys Gln Ser Ser Gln Leu Asp Glu Asp Arg
2585 2590 2595
Thr Glu Ala Ala Asn Arg Ile Ile Cys Thr Ile Arg Ser Arg Arg
2600 2605 2610
Pro Gln Met Val Arg Ser Val Glu Ala Leu Cys Asp Ala Tyr Ile
2615 2620 2625
Ile Leu Ala Asn Leu Asp Ala Thr Gln Trp Lys Thr Gln Arg Lys
2630 2635 2640
Gly Ile Asn Ile Pro Ala Asp Gln Pro Ile Thr Lys Leu Lys Asn
2645 2650 2655
Leu Glu Asp Val Val Val Pro Thr Met Glu Ile Lys Val Asp His
2660 2665 2670
Thr Gly Glu Tyr Gly Asn Leu Val Thr Ile Gln Ser Phe Lys Ala
2675 2680 2685
Glu Phe Arg Leu Ala Gly Gly Val Asn Leu Pro Lys Ile Ile Asp
2690 2695 2700
Cys Val Gly Ser Asp Gly Lys Glu Arg Arg Gln Leu Val Lys Gly
2705 2710 2715
Arg Asp Asp Leu Arg Gln Asp Ala Val Met Gln Gln Val Phe Gln
2720 2725 2730
Met Cys Asn Thr Leu Leu Gln Arg Asn Thr Glu Thr Arg Lys Arg
2735 2740 2745
Lys Leu Thr Ile Cys Thr Tyr Lys Val Val Pro Leu Ser Gln Arg
2750 2755 2760
Ser Gly Val Leu Glu Trp Cys Thr Gly Thr Val Pro Ile Gly Glu
2765 2770 2775
Phe Leu Val Asn Asn Glu Asp Gly Ala His Lys Arg Tyr Arg Pro
2780 2785 2790
Asn Asp Phe Ser Ala Phe Gln Cys Gln Lys Lys Met Met Glu Val
2795 2800 2805
Gln Lys Lys Ser Phe Glu Glu Lys Tyr Glu Val Phe Met Asp Val
2810 2815 2820
Cys Gln Asn Phe Gln Pro Val Phe Arg Tyr Phe Cys Met Glu Lys
2825 2830 2835
Phe Leu Asp Pro Ala Ile Trp Phe Glu Lys Arg Leu Ala Tyr Thr
2840 2845 2850
Arg Ser Val Ala Thr Ser Ser Ile Val Gly Tyr Ile Leu Gly Leu
2855 2860 2865
Gly Asp Arg His Val Gln Asn Ile Leu Ile Asn Glu Gln Ser Ala
2870 2875 2880
Glu Leu Val His Ile Asp Leu Gly Val Ala Phe Glu Gln Gly Lys
2885 2890 2895
Ile Leu Pro Thr Pro Glu Thr Val Pro Phe Arg Leu Thr Arg Asp
2900 2905 2910
Ile Val Asp Gly Met Gly Ile Thr Gly Val Glu Gly Val Phe Arg
2915 2920 2925
Arg Cys Cys Glu Lys Thr Met Glu Val Met Arg Asn Ser Gln Glu
2930 2935 2940
Thr Leu Leu Thr Ile Val Glu Val Leu Leu Tyr Asp Pro Leu Phe
2945 2950 2955
Asp Trp Thr Met Asn Pro Leu Lys Ala Leu Tyr Leu Gln Gln Arg
2960 2965 2970
Pro Glu Asp Glu Thr Glu Leu His Pro Thr Leu Asn Ala Asp Asp
2975 2980 2985
Gln Glu Cys Lys Arg Asn Leu Ser Asp Ile Asp Gln Ser Phe Asn
2990 2995 3000
Lys Val Ala Glu Arg Val Leu Met Arg Leu Gln Glu Lys Leu Lys
3005 3010 3015
Gly Val Glu Glu Gly Thr Val Leu Ser Val Gly Gly Gln Val Asn
3020 3025 3030
Leu Leu Ile Gln Gln Ala Ile Asp Pro Lys Asn Leu Ser Arg Leu
3035 3040 3045
Phe Pro Gly Trp Lys Ala Trp Val
3050 3055
Claims (13)
4、一种ATR抑制剂,其特征在于含有下式(4)所示的化合物作为有效成分:
11、根据权利要求1-10任一项中记载的ATR抑制剂,其特征在于前述ATR活性为蛋白质磷酸化活性。
12、根据权利要求11中记载的ATR抑制剂,其特征在于前述蛋白质磷酸化活性为对细胞周期关联蛋白质进行磷酸化的活性。
13、根据权利要求12中记载的ATR抑制剂,其特征在于前述细胞周期关联蛋白质为p53。
14、根据权利要求12或13中记载的ATR抑制剂,其特征在于前述细胞周期关联蛋白质选自于Brca1和Chk1构成的组中。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP307534/2005 | 2005-10-21 | ||
JP2005307534 | 2005-10-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101291668A true CN101291668A (zh) | 2008-10-22 |
Family
ID=37962519
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2006800391066A Pending CN101291668A (zh) | 2005-10-21 | 2006-10-18 | Atr抑制剂 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20100048923A1 (zh) |
EP (1) | EP1946757A1 (zh) |
JP (1) | JPWO2007046426A1 (zh) |
CN (1) | CN101291668A (zh) |
CA (1) | CA2626681A1 (zh) |
WO (1) | WO2007046426A1 (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009047488A1 (en) * | 2007-10-09 | 2009-04-16 | The Council Of The Queensland Institute Of Medical Research | Method of screening for anticancer agents |
EP2724156B1 (en) | 2011-06-27 | 2017-08-16 | The Jackson Laboratory | Methods and compositions for treatment of cancer and autoimmune disease |
JP2013209299A (ja) * | 2012-03-30 | 2013-10-10 | Kose Corp | Dna損傷抑制剤並びにこれを含有する皮膚外用剤、化粧料および飲食物 |
US20240025899A1 (en) | 2020-10-16 | 2024-01-25 | Shanghai De Novo Pharmatech Co., Ltd. | Triheterocyclic derivative, and pharmaceutical composition and application thereof |
AU2022284632A1 (en) * | 2021-06-04 | 2023-12-07 | Repare Therapeutics Inc. | Crystalline forms, compositions containing same, and methods of their use |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0248592A (ja) * | 1988-08-09 | 1990-02-19 | Tsumura & Co | ジベンゾシクロオクタジエン型リグナンの製造法 |
-
2006
- 2006-10-18 JP JP2007541012A patent/JPWO2007046426A1/ja active Pending
- 2006-10-18 CA CA002626681A patent/CA2626681A1/en not_active Abandoned
- 2006-10-18 US US12/090,898 patent/US20100048923A1/en not_active Abandoned
- 2006-10-18 WO PCT/JP2006/320756 patent/WO2007046426A1/ja active Application Filing
- 2006-10-18 CN CNA2006800391066A patent/CN101291668A/zh active Pending
- 2006-10-18 EP EP06811953A patent/EP1946757A1/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
JPWO2007046426A1 (ja) | 2009-04-23 |
US20100048923A1 (en) | 2010-02-25 |
CA2626681A1 (en) | 2007-04-26 |
EP1946757A1 (en) | 2008-07-23 |
WO2007046426A1 (ja) | 2007-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhang et al. | Fibrillogenic amylin evokes islet β-cell apoptosis through linked activation of a caspase cascade and JNK1 | |
Chung et al. | Control of adipogenesis by the SUMO-specific protease SENP2 | |
Cai et al. | Spop promotes skeletal development and homeostasis by positively regulating Ihh signaling | |
Khalil et al. | Caspase-3 protects stressed organs against cell death | |
Berger et al. | Parkin selectively alters the intrinsic threshold for mitochondrial cytochrome c release | |
US6887853B2 (en) | Use of geldanamycin and related compounds for treatment of fibrogenic disorders | |
Zhang et al. | Increased expression and activation of c-Jun contributes to human amylin-induced apoptosis in pancreatic islet β-cells | |
US20080220056A1 (en) | Treatment for liver disease | |
Tanimoto et al. | A soluble form of fibroblast growth factor receptor 2 (FGFR2) with S252W mutation acts as an efficient inhibitor for the enhanced osteoblastic differentiation caused by FGFR2 activation in Apert syndrome | |
JP2015180657A (ja) | 細胞及び生物の寿命を延ばし、ストレス耐性を高めるための方法及び組成物 | |
Sever et al. | Isolation of mutant cells lacking Insig-1 through selection with SR-12813, an agent that stimulates degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase | |
CN101291668A (zh) | Atr抑制剂 | |
Canalis et al. | Antisense oligonucleotides targeting Notch2 ameliorate the osteopenic phenotype in a mouse model of Hajdu-Cheney syndrome | |
Zhang et al. | Nitric oxide induces tau hyperphosphorylation via glycogen synthase kinase-3β activation | |
KR20140129617A (ko) | 지방세포 분화 과정에서 인간 작은 류신 지퍼 단백질의 용도 | |
Qu et al. | Vitamin C Treatment Rescues Prelamin A‐Induced Premature Senescence of Subchondral Bone Mesenchymal Stem Cells | |
Stout et al. | STAT1 activation causes translocation of Bax to the endoplasmic reticulum during the resolution of airway mucous cell hyperplasia by IFN-γ | |
Zhang et al. | Protective effects of Notch1 signaling activation against high glucose-induced myocardial cell injury: analysis of its mechanisms of action | |
Siemann et al. | Inhibition of cyclic AMP response element-binding protein/cyclic AMP response element-mediated transcription by the immunosuppressive drugs cyclosporin A and FK506 depends on the promoter context | |
Chen et al. | Neurotrophic effects of serum-and glucocorticoid-inducible kinase on adult murine mesencephalic dopamine neurons | |
Muñiz et al. | Transcriptional regulation of cyclin D2 by the PKA pathway and inducible cAMP early repressor in granulosa cells | |
CN106659911B (zh) | 治疗或预防神经退行性病症的组合物和方法 | |
Zhang et al. | Kinetin inhibits proliferation of hepatic stellate cells by interrupting cell cycle and induces apoptosis by down-regulating ratio of Bcl-2/Bax | |
US20070065804A1 (en) | Method for PR-39 peptide mediated selective inhibition of IkappaBalpha degradation | |
Shetty et al. | p53-dependent apoptosis in the inhibition of spermatogonial differentiation in juvenile spermatogonial depletion (Utp14b jsd) mice |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |